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1 Zusammenfassung
Natürliche Killer (NK) Zellen sind wichtige Eﬀektorzellen in Hepatits C Virus (HCV)
Infektionen. HCV ist ein Virus mit dem ca. 2.5% der Weltbevölkerung chronisch
infiziert ist und der einen wesentlichen Anteil zu Lebererkrankungen und Leberkrebs
beiträgt. Die genauen Mechanismen durch welche NK Zellen von HCV aktiviert werden
sind jedoch noch unklar.
Mit Hilfe des HCV Replikon Zellkultursystems konnten wir nachweisen, dass nach Co-
Kultur von Replikon-tragenden Hepatozyten und mononukleären Zellen des peripheren
Blutes (PBMCs) eine Subpopulation von NK Zellen die Expression der hoch-aﬃnen IL-2
Rezeptorkette CD25 steigerte, verstärkt proliferiert hatte und mehr IFN-  produzierte.
Die Aktivierung von NK Zellen war abhängig von IL-2, welches sehr wahrscheinlich
von T Zellen produziert wurde, und von Zell-Zell-Kontakt vermittelten Signalen von
Monozyten. Diese zeigten in Co-Kulturen mit HCV Replikon eine erhöhte Expres-
sion von OX40L, einem Mitglied der Tumornekrosefaktor-Familie. Gleichzeitig war der
Rezeptor OX40 auf NK Zellen stärker exprimiert. Blockade von OX40L und Depletion
von Monozyten verhinderten die Virus-bedingte Aktivierung und gesteigerten Eﬀektor-
funktionen von NK Zellen.
Zusammenfassend zeigen unsere Daten einen neuen Mechanismus der Monozyten- ver-
mittelten Aktivierung von NK Zellen gegen virusinfizierte Zellen und die Wichtigkeit der
OX40/ OX40L Achse mit einer potentiellen Relevanz für eine therapeutische Interven-
tion durch z.B. agonistische Antikörper gegen OX40, welche bereits in der Krebstherapie
getestet werden.
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2 Summary
Natural Killer (NK) cells are important eﬀector cells in Hepatitis C Virus (HCV) infec-
tion, a virus that chronically infects around 2.5% of the world population and is a major
cause of liver disease and hepatocellular carcinoma. The exact mechanisms, however,
through which NK cells are activated in response to HCV remain elusive.
Using the well-established HCV replicon cell-culture model we show that after co-
culture of HCV replicon-carrying hepatocytes with peripheral blood mononuclear cells
(PBMCs), NK cells increase expression of the high-aﬃnity IL-2 receptor chain CD25,
proliferate rapidly and produce IFN- . Activation of NK cells was dependent on IL-2,
most likely produced by T cells and on cell-cell contact mediated signals from mono-
cytes. Monocytes from replicon-carrying co-cultures showed increased expression of
OX40L, a member of the tumor necrosis factor family and concurrently its receptor
OX40 was increased on NK cells. Blocking of OX40L in those co-cultures, as well
as depletion of CD14+ monocytes abrogated the virus-induced activation and eﬀector
functions of NK cells.
Together, our data reveals a novel mechanism of monocyte mediated NK cell activation
against virus-infected cells involving the OX40/OX40L axis with potential relevance for
therapeutic intervention by e.g. agonistic antibodies against OX40, which are already
tested in cancer therapy.
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3 Introduction
3.1 The human immune system
Every living organism - from the smallest bacteria through plants and animals to hu-
mans - is constantly exposed to pathogens. Throughout evolution, in ever more complex
ways, all of these species have developed manifold strategies to protect themselves from
harm. Emerged from this has the human immune system - the most complex immune
system we know.
As manifold as the pathogens and their sites of infection are, as manifold are the de-
fence mechanism of the body. The easiest and probably most eﬀective defence are the
physical, chemical and biological surface barriers. In humans, already an intact epithe-
lial surface wards oﬀ many bacteria, protozoa, worms, fungi or viruses. Those areas
not covered by epithelial, such as the gastro-intestinal tract and the respiratory system
have strategies such as the low pH in the stomach that kills many pathogens that are
ingested with food. The lungs are covered with mucus that traps bacteria and lined
with cilia, that move the mucus out. Furthermore mucus, saliva, tears and other body
fluid contain anti-microbial substances, such as the  -defensin peptides or the enzyme
lysozyme, both of which can destroy the integrity of the invaders outer membrane.
However, pathogens have evolved eﬀective mechanisms to counteract the body’s defence
and are therefore able to enter and infect the blood and organs of the body.
To eﬃciently guard the body, the immune system is spatially distributed, with immune
cells and other immune components being present in virtually every organ and tissue.
Furthermore many organs have developed tissue-specific immunity.
The function of the immune system is based on the principle of self vs. non-self discrim-
ination. This discrimination is achieved via a plethora of receptors which can recognise
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foreign, non-self structures on pathogens, but also altered-self structures, such as muta-
tions in cancer cells. One type of receptors are the so-called pattern recognition recep-
tors (PRRs). They are invariable, germ-line encoded receptors that recognise conserved
structures on pathogens, called pathogen-associated molecular patterns (PAMPs). The
second type of receptors are the highly variable T cell receptors (TCRs) and B cell re-
ceptors (BCRs), where each receptor recognises only one specific structure, its antigen.
Based, amongst other criteria, on the two types of receptors the immune system can be
divided into two branches - the innate and the adaptive immune system, with each of
these branches having a humoral and a cellular part (1 ).
3.1.1 The adaptive immune system
One of the key features of the adaptive immune system is immunological memory which
is conferred by the highly-diverse antigen-specific receptors present on T and B cells.
Upon encountering their cognate antigen, T or B cells carrying the specific receptor un-
dergo clonal expansion, maturation and subsequently a pool of memory cells is formed.
These memory cells can ’remember’ the previous antigen-encounter and, upon a sec-
ondary infection with the same pathogen, mount a faster and stronger secondary re-
sponse. Immunological memory is the basis of a successful vaccination.
Although the adaptive immune system, as we understand it, only developed in jawed
vertebrates, it is now known that already bacteria can remember and more eﬀectively
fight a secondary infection from e.g. bacteriophages by using the CRISPR-Cas sys-
tem.
The cells of the human adaptive immune system are T and B cells. T and B lympho-
cytes, like all leukocytes, are produced in the bone marrow from hematopoietic stem
cells and T cells are further diﬀerentiated in the thymus. Each T cell expresses a unique
TCR which is composed of an ↵- and a  -chain and produced in a process termed so-
matic V(D)J recombination. recombination-activating gene (RAG)1/2 recombinases,
randomly combine genetic elements from the TCR locus to form both chains. The en-
tire TCR rearrangement process can produce 1014-1018 TCRs with diﬀerent specificity.
T cells with unsuccessfully recombined chains, non-reactive and self-reactive TCRs are
afterwards depleted in the thymus. The BCR is produced in a similar process and
composed of 2 heavy transmembrane chains and two light chains. The BCR binds to
antigens in their native configuration and can therefore detect extracellular bacteria
and neutralise toxins. B cells can shed their BCRs into the plasma, where they are
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called Immunoglobulins (Ig) or antibodies. There are five diﬀerent Ig isoforms: IgA,
IgD, IgE, IgG and IgM each with diﬀerent functions and localisation, which make up
the humoral part of the adaptive immune system.
The TCR recognises its cognate antigen only when it is presented in major histocom-
patibility complexs (MHCs). CD8+ cytotoxic T cells recognise peptides presented in
MHC-I, which is expressed on every nucleated cell. Activation of CD8 T cells via the
TCR and co-stimulatory molecules results in killing of the target cell. CD4+ helper
T cells recognise peptides presented in MHC-II molecules, which are only present on
specific antigen-presenting cells (APCs), such as macrophages, dendritic cells (DCs)
or B cells. Activated CD4 T cells help for example macrophages to more eﬃciently
phagocytose or B cells to produce antibodies.
Once a lymphocyte becomes activated it undergoes clonal proliferation to increase the
number of cells specific for the pathogen (1 ) (2 ).
3.1.2 The innate immune system
The innate immune system is evolutionary much older than the adaptive immune system
and found in diﬀerent complexities in nearly all life forms.
In humans, the innate immune system is composed of the already mentioned surface
barriers, a humoral part, primarily consisting of the complement system and a cellular
part, which includes phagocytic cells (macrophages/ monocytes, dendritic cells and
neutrophils), mast cells, eosinophils, basophils and innate lymphoid cells (ILCs), to
which Natural killer (NK) cells belong.
The innate immune system is the first line of defense against invading pathogens, as
it can act fast, without the need of prior activation, in a generic, antigen-independent
manner. The innate immune system is activated via its germ-line encoded invariant
PRRs that recognise e.g. viral and bacterial proteins and RNA/DNA. The most promi-
nent class of PRRs are the Toll-like receptors (TLRs). Table 3.1 summarizes the human
TLRs, their main ligands and cellular location. Monocytes/ Macrophages express al-
most all TLRs summarized in table 3.1, but many of the TLRs are also expressed on
neutrophils, DCs, mast cells and also on B cells. More recently mRNA expression of
diﬀerent TLRs was observed in human NK cells. Data are still controversial, but most
studies observed expression of TLR1, 2, 3, 5 and 6. TLR2 could also be detected on pro-
tein level by flow cytometry after cytokine activation. When stimulated with diﬀerent
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PAMPs or TLR agonists and cytokines such as IL-2, IL-12, IL-15 or IL-18, isolated NK
cells were able to produce IFN- . In general, it has been observed that the activation of
NK cells by PAMP seems to depend on the presence of activating cytokines produced
by accessory cells (3 ).
All TLRs, except TLR3, use MyD88 as an adaptor protein, which leads to the ac-
tivation of the immunological master transcription factor nuclear factor kappa-light-
chain-enhancer of activated B cell (NF-B) and the activation of mitogen-activated pro-
tein (MAP) Kinases. TLR3 uses the adaptor TIR-domain-containing adapter-inducing
interferon-  (TRIF), which also activates NF-B, but furthermore activates Interferon
regulatory factor (IRF)3, leading to the production of type I Interferons (IFNs) (1 )
(2 ).
Table 3.1: Toll-like receptors and their ligands
Receptor Ligand Cellular Location
TLR 1 triacyl lipopeptides plasma membrane
TLR 2 lipopeptides, glycopeptides plasma membrane
TLR 3 double-stranded RNA, poly I:C endosome
TLR 4 lipopolysaccharide (LPS) plasma membrane
TLR 5 flagellin, profilin plasma membrane
TLR 6 diacyl lipopeptides plasma membrane
TLR 7 single-stranded RNA endosome
TLR 8 single-stranded RNA endosome
TLR 9 unmethylated CpG DNA endosome
TLR 10 unknown unknown
While the TLRs are restricted to the plasma membrane and the endo-/lysosome, other
PRRs are present in the cytoplasm, namely the Rig-like receptors (RLRs), NOD-like
receptors (NLRs) and Aim2-like receptors (ALRs). For intracellular viral recognition,
the family of RLRs, consisting of retinoic acid-inducible gene-I (RIG-I), melanoma
diﬀerentiation gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) are of
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great importance. RIG-I recognises short, uncapped RNA and MDA5 double-stranded
RNA. In general, they recognise RNA structures, which are common to viral RNA or
viral replication intermediates, such as long double-stranded RNA or the poly-uridine
region in the HCV genome. RIG-I and MDA5 recruit the adaptor protein mitochondrial
antiviral signaling protein (MAVS) via its CARD-domain. This leads to the activation
of NF-B, IRF3 and IRF7 and thereby to the expression of pro-inflammatory cytokines
such as IFNs and the transcription of IFN-stimulated genes (ISG), putting the cell into
an anti-viral state (4 ).
In accordance with their function as intracellular pathogen sensors, expression of the
RLRs, NLRs and ALRs is not restricted to the immune system, but found in various
cell types throughout the body. E.g. RIG-I is highly expressed in the liver and muscle
(5 ).
Monocytes and Macrophages
Monocytes are produced in the bone marrow from the common myeloid progenitor,
which gives rise to the granulocyte-monocyte precursor, which eventually produces
monocytes. They compose around 10% of leukocytes in the blood. Once they enter a
tissue they diﬀerentiate into macrophages. Depending on their location macrophages
have diﬀerent names and organ-specific functions. In the liver for example, they are
called Kupﬀer cells, in the brain microglia and in the lung alveolar macrophages.
Monocytes and macrophages are professional phagocytic cells and crucial players in the
innate immune defence. They can engulf pathogens or cancer cells, but also clean up cel-
lular debris and apoptotic cells, which is of importance in tissue repair and remodelling
and during development.
Besides their direct anti-pathogenic functions, they play an extremely important role in
shaping the overall immune response to a pathogen. Firstly, monocytes can produce a
wide array of pro- and anti-inflammatory cytokines such as tumor necrosis factor-alpha
(TNF-↵) and Interleukin-10 (IL-10) and chemokines after stimulation with e.g. TLR-
ligands, which regulate and attract other immune cells. Secondly, they are professional
APCs. After TLR-activation and phagocytosis of a pathogen they process pathogenic
antigens and present them in MHC-II molecules to CD4 T cells that carry the TCR
specific for this particular antigen to activate them. This way monocyte form a bridge
between the innate and adaptive immune system (1 ) (2 ).
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Macrophages can be classified into three major subtypes according to their surface
expression of CD14, a co-receptor for TLR4, and Fc RIII CD16. CD14++ CD16  are
classical monoytes, CD14++ CD16+ are intermediate monocytes and CD14+ CD16++
are the non-classical monocytes (6 ).
Another classification is made according to their way of activation and the thereof re-
sulting function into classically activated M1 macrophages and alternatively activated
M2 macrophages. M1 type macrophages have a pro-inflammatory phenotype, which
promotes killing of intracellular pathogens and tumour resistance. They develop af-
ter stimulation with e.g. Interferon-gamma (IFN- ), LPS, granulocyte macrophage
colony-stimulating factor (GM-CSF) or after intracellular TLR activation by viruses.
Functionally they upregulate inducible nitric oxide synthase (iNOS) to increase pro-
duction of the free radical nitric oxide (NO), increase antigen-presentation and T cell
co-stimulation via high expression of MHC-II and CD86. Furthermore they produce IL-
12, IL-1, IL-6 and TNF-↵. M2 macrophages on the other hand have diverse functions
in allergy, immune responses to parasites and in the promotion of tissue repair. They
are amongst others stimulated by IL-4, IL-10 and IL-13 and produce cytokines such as
IL-10 or transforming growth factor-beta (TGF- ) (7 ).
3.2 Natural Killer Cells
NK cells have been identified in mice in 1975, when researchers observed a ’natural’,
spontaneous cytotoxicity against certain tumor cell lines from splenic cells (8 )(9 ). They
have been termed ’natural’ killer cells, because, unlike e.g. T cells, they did not require
sensitisation or priming prior to exerting their eﬀector functions. The fact that these
killer cells with natural cytotoxicity were specifically recognising targets that had low or
no MHC-I expression, which is a sign of transformation or infection of a cell, led, more
than 10 years after their first description, to the discovery of their mode-of-activation,
when Klas Kärre and Rolf Kiessling proposed the ’missing-self’ hypothesis (10 ). This
states that NK cells do not only, like other immune cells, become activated by the pres-
ence of non-self structures, but can also recognise infected/transformed cells via the
absence of self-structures, in this case MHC-I. Today we know that NK cells express
a great number of receptors, primarily belonging the killer-cell immunoglobulin-like re-
ceptor (KIR) family of receptors, that can bind MHC-I molecules and inhibit NK cell
activation. Together with signals derived from activating receptors, that mainly recog-
nise stress-induced ligands, the activation status of an NK cells is defined. Activation
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of NK cells not only leads to target cell killing, in addition NK cells are also potent cy-
tokine producers, the key cytokine being IFN- , through which they play an important
part in orchestrating the overall immune response.
NK cell receptors are germ-line encoded and do not undergo genetic recombination
by RAG1/2. Therefore NK cells are classified as innate immune cells, although they
share a common progenitor cell with T and B lymphocytes and many functional and
transcriptional similarities to CD8 T cells. Of note, a recent publication reported a role
for the RAG recombinase in NK cell development and cellular fitness (11 ). Since a few
years, we now appreciate that NK cells are not the only innate cells that are derived
from the common lymphoid progenitor cell, but do, in fact, belong to a whole group of
ILCs (1 ) (2 ).
3.2.1 NK cell definition, development and subsets
Definition
NK cell are cytotoxic lymphocytes that constitute around 5% of leukocytes or 10% of
lymphocytes in the peripheral blood. Phenotypically NK cells are clasically defined
as CD3  (non-T) cells that express CD56, an isoform of neural cell adhesion molecule
(NCAM). CD3 has to be excluded because CD56 is also expressed on CD3+ NKT
cells. More recently, NKp46 has been proposed as a more exclusive and general NK cell
marker, as NKp46, unlike CD56, is also expressed on mouse NK cells (12 ). Furthermore
the occurence of CD56  NK cells has been observed in certain viral infections, which
also encourages the use of NKp46 as an NK cell marker (13 ). However, expression
of NKp46 can also be found under certain conditions on subsets of T cells (14 ) and
it is also expressed on ILCs3 and ILC1 subsets (15 ). As long as no unique NK cell
marker has been identified, CD56 and NKp46 will be used, with the above mentioned
reservations in mind.
Development
NK cells develop in the bone marrow from Lin  CD34+ hematopoietic stem cells. How-
ever, this may not be the only site of NK cell development, as NK cell precursors are
also present in the circulation and CD34+ NK precursors are enriched in other lymphoid
and non-lymphoid organs, such as the thymus, lymph nodes, the gastrointestinal tract
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or the liver. (16 ). Compared to mouse NK cell development, rather little is known
about NK precursors in humans and much of the data comes from ex vivo diﬀerentia-
tion experiments.
In humans it is thought that NK cells and ILCs develop from the same common lym-
phoid progenitor as T and B cells. During the commitment to the NK cell lineage, the
aquisition of CD122, the IL-15 receptor   chain, marks an important step. IL-15 is
crucial for NK cell homeostasis and promotes survival and proliferation of NK cells. In
vitro IL-15 is also capable to diﬀerentiate CD34+ hematopoietic progenitor cells into NK
cells (16 ). Immature NK cells do not yet express inhibitory KIRs and CD94/NKG2A
on their surface, making them potentially auto-reactive, but it is commonly thought
that they do not yet possess eﬀector functions. During further maturation NK cells ac-
quire KIR, CD94/NKG2A, CD56, NKp46, CD16 and Natural Killer group 2, member
D (NKG2D).
NK cell education
The acquisition of KIRs is a stochastic process, which leaves some NK cells expressing
no KIRs at all, others expressing one or even multiple diﬀerent KIRs. Studies have
shown, that mature NK cells that lack expression of inhibitory receptors are in fact,
not hyper- but hyporesponsive. Furthermore it was shown that the signaling motifs
of inhibitory receptors (Immunoreceptor tyrosine-based inhibitory motifs (ITIMs)) are
crucial to achieve proper responsiveness of NK cells. Out of this and many other obser-
vations, the concept of NK cell education has developed (17 ). NK cells are activated by
the sensing of ’missing-self’ and according to the NK cell education concept, in order
to do so, NK cells have to be educated to the normal MHC-I environment of the host.
During NK cell education, those NK cells that express many inhibitory receptors that
have a matching MHC-I allele or express inhibitory receptors with high aﬃnity for their
respective ligand become ’licensed’ to excert greater eﬀector functions after stimulation
(18 ).
Besides KIRs, the CD94/NKG2A heterodimeric receptor, which recognises the non-
classical MHC-I molecule HLA-E, also plays a role in NK cell licensing. CD94/NKG2A
is presumably of even greater importance in the early stages of NK cell maturation.
As of now, the prevailing opinion is that committed NK cells first acquire a CD56bright
phenotype and during maturation reduce CD56 expression. Almost all CD56bright NK
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cells are expressing CD94/NKG2A, but little or no KIRs. This balance is reversed
during the maturation into CD56dim NK cells. Only about half of the CD56dim NK cell
subset expresses CD94/NKG2A (17 ).
Of note, this does not mean that uneducated NK cells cannot become activated and
exert eﬀector functions. In fact, under certain conditions, they might even perform
better than their educated counterparts. For example, they have been shown to better
react to MHC-I+ cancer cells and be superior in the clearance of murine cytomegalovirus
(MCMV) (17 ).
NK cell subsets
The two major NK cell subsets are, as already mentioned, the CD56dim and the
CD56bright subset, which are though to represent two phases in a linear NK matu-
ration model. The more immature CD56bright subset, which comprises around 10% of
the blood NK cells under homoeostasis, but it the prevalent NK subset in secondary
lymphoid organs, has a high potential to produce cytokines, but is less cytotoxic than
the CD56dim NK cells. The CD56dim subset has a high cytotoxic potential and due to
the co-expression of CD16 (which lacks in CD56bright cells) has the potential to exert
antibody-dependent cellular cytotoxicity (ADCC). CD16 recognises the constant re-
gion of the heavy chain on an antibody, the Fc-part, bound to its antigen and thereby
triggers NK cell degranulation. Of note, this classification is somewhat simplified and
under the right conditions, both subsets can be cytotoxic and cytokine expressing.
3.2.2 NK cell receptors, ligands and their activation
NK cells have a plethora of activating and inhibitory receptors on their surface, as well
as cytokine, chemokine and adhesion receptors. They can be classified into several sub-
groups, according to their structure, function and/or ligands. Most activating receptors
signal via immunoreceptor tyrosine-based activation motifs (ITAMs), most inhibitory
via ITIMs in their cytoplasmic tail or associated receptors/ adaptors. ITIM activation
activates phosphatases such as SHP-1/2 or SHIP which dephosphorylate and thereby
inhibit the function of further downstream eﬀectors, while ITAM activation stimulates
phosphorylation, e.g.. via phosphatidylinositol-3 kinase (PI3K), of those downstream
eﬀectors. The integration of all signals from inhibitory and activating receptors finally
decides if an NK cell is activated or not.
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Natural Cytotoxicity Receptors
One major group of activating NK cell receptors are the natural cytotoxicity recep-
tors (NCRs). Members of this family of receptors include NKp46, NKp30, NKp44 and
NKp80. They all contain one or two immunoglobulin-like domains and couple to intra-
cellular adaptor molecules expressing ITAMs. Besides that they do not share sequence
homology, but are rather grouped together because of their potential to activate NK
cells (19 ).
NKp46 is constitutively expressed on all NK cells and NKp30 is found on all mature
NK cells (20 ). NKp44 is not expressed in steady-state, but inducible after activation
(21 ). For many of the NCRs, the ligands are poorly defined, especially the cellular
ligands. The first ligands that were discribed for NKp46, NKp44 and NKp30 were, ac-
tually, viral proteins. Hemagglutinin neuraminidases (HN) and haemagglutinins (HAs)
of diﬀerent viruses, such as influenza, Sendai virus, vaccina virus or Newcastle dis-
ease virus have been shown to bind to some of these NCRs (19 ). Furthermore human
cytomegalovirus (HCMV) tegument protein pp65 can bind to NKp30 (22 ). Cellular
ligands include proliferating cell nuclear antigen (PCNA) and NKp44L for NKp44 and
B7-H6 for NKp30, which is one of the few extracellular ligands described on the cell
surface of tumour cells (23 )(24 ).
Natural Killer Group 2 Receptors
The class of Natural killer group 2 receptors on NK cells includes activating as well as
inhibitory receptors. NKG2C, NKG2E and NKG2D are the activating forms belonging
to this C-type lectin-like family of receptors and NKG2A is inhibitory. NKG2D is
among the best studied NK receptors. It is expressed on almost all NK cells, but
also on T cells, where is acts mainly as an co-stimulatory molecule. It signals via the
adaptor molecule DAP-10 and recognises the stress-induced MHC-I homologues MHC
class I polypeptide-related sequence A (MIC-A) and MHC class I polypeptide-related
sequence B (MIC-B) and UL16 binding protein (ULBP)1-6 (25 ). Other members of
the NKG2 family have the non-classical HLA-E molecule as ligand.
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Killer-cell Immunoglobulin-like Receptors
The KIRs are a highly polymorphic group of receptors binding to the equally poly-
morphic MHC-I molecules on target cells. Most of the known KIRs are inhibitory, but
some, lesser defined KIRs, are also activating NK cells. The KIRs are involved in the
already mentioned ’missing-self’ activation of NK cells and in the licensing/education
process during NK development.
TNF-Receptor Superfamily
While the NCRs, NKG2 receptors and KIRs are receptors that are primarily expressed
on NK cells, the expression of the members of the tumor necrosis factor receptor super-
family (TNFRSF) and their ligands, the tumor necrosis factor superfamily (TNFSF)
are widely expressed in lymphoid and non-lymphoid tissues and play a major role in
adaptive and innate immune responses against pathogens and also in cancer by facili-
tating death of an infected/transformed cell, but also by modulating immune cells. NK
cells are known to express several TNFRSFs and TNFSF members.
This family of receptors is further subdivided into two subgroups: the death domain-
containing receptors (e.g. Fas, TRAIL-receptors (TRAIL-Rs), tumor necrosis factor
receptor (TNFR)1) whose activation induces caspase activation and apoptosis and the
TNFR-associated factor (TRAF)-binding receptors (eg. OX40, CD40, HVEM, GITR,
4-1BB, CD27, CD30) which activate transcription factors like NF-B and are therefore
involved in cell activation, survial and diﬀerentiation (26 ).
TNFSF members are often induced after NK cell activation and serve as eﬀector
molecules that induce cell death in a target cell. The TNFSF members expressed
by NK cells include the prototypic TNF-↵ as well as FasL and TNF-related apoptosis
inducing ligand (TRAIL), which lead to the induction of apotosis in the target cell.
Furthermore NK cells express HVEM ligands LIGHT, Lymphotoxin-↵/ , BTLA and
CD160, whose interaction with HVEM is rather complicated, as it can be inhibitory or
activating depending on the ligands (LIGHT and Lymphotoxin binding is thought to
promote inflammation and BTLA and CD160 is rather anti-inflammatory). And also
because HVEM signalling can be bidrectional, as many of the ligands have signalling
capacity themselves. NK cells express not only the ligands for HVEM, but also HVEM
itself (27 ) (28 ).
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Other TNFRSF members expressed by NK cells are GITR and 4-1BB. 4-1BB is almost
absent and GITR only expressed at low levels on resting human NK cells, but both
can be induced after e.g. cytokine activation. For both receptors activating as well as
inhibitory functions have been described for NK cells, while on T cells they work as
co-stimulatory molecules. 4-1BB and GITR agonistic antibodies are in clinical trials to
boost T cell anti-cancer eﬃciency. In NK cells the context of GITR or 4-1BB stimulation
may be important to determine the outcome of receptor engagement. Possible factors
include the cytokine milieu, the nature of the cell expressing the ligand, or the form of
the ligand (soluble vs. cell-bound) (26 ).
TNFSF-Receptor OX40 and its ligand OX40L OX40 (also known as CD134 or TN-
FRSF4) is best known as a co-stimulatory receptor on T cells, primarily on CD4+ T
cells, but can also be expressed on NK, NKT cells and neutrophils. Data on the function
of OX40 on NK cells is sparse, but all studies indicate it to function as an activating
receptor as well. On almost all cell types OX40 is not expressed in the naive state, but
has to be induced by activation. However, reports show constitutive expression on CD4
T follicular helper cells (29 ).
In T cells OX40 is induced after TCR and CD28 or CD40 engagement in a sequential
manner, making it a late co-stimulatory molecule. The exact timing and duration of
OX40 induction varies drastically between diﬀerent experimental conditions and cy-
tokine stimulation (eg. IL-1, IL-2, IL-4 or TNF) can also prolong and induce the
expression of OX40 (30 ) (31 ).
OX40 can act as an independent receptor, like other TNFRs super family members,
by recruiting several TRAF proteins and activating NF-B. This results in enhanced
cell survival. Furthermore, in collaboration with TCR signalling, it can activate both,
NF-B and the PI3K-Akt pathway, which leads to the stabilization of high levels of anti-
apoptotic Bcl-2 family members (enhances survival), the induction of several molecules
involved in cell cyle progression, such as survivin and cyclin A (enhances proliferation)
and the production of cytokines (30 ). One cytokine that is produced by eﬀector CD4 T
cells after OX40 ligation is IL-2. Simultaneously expression of the IL-2R↵ chain (CD25)
is upregulated. Enhanced IL-2 signalling then promotes IFN-  production of T cells in
response to cytokines such as IL-12 or IL-18. Other eﬀects of OX40 signaling on CD4 T
cells include upregulation of IL-12R 2 chain and downregulation of anti-inflammatory
mediators such as CTLA-4 and IL-10 (30 ).
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Initial studies performed in OX40 knock-out mice showed that besides impaired survival,
proliferation and cytokine production, also memory formation and maintenance was
aﬀected. Specific expression and importance of OX40 in memory T cells was then
also confirmed in humans. When human CD4 memory T cells are rechallenged in
vitro with viral, bacterial or autoantigens, they rapidly start to express OX40. In many
reports OX40 expression coincides with CD25 upregulation. Co-expression of OX40 and
CD25 on memory cells is now used in the clinics to determine whether a patient has
encountered a specific pathogen before or is reactive to autoantigens (32 ). Keoshkerian
et al. could show that HCV-specific CD4 memory cells upregulate OX40 and CD25
after stimulation with recombinant viral peptides or proteins and viral supernatants.
This helps in identifiying patients with chronic and resolved HCV infection (33 ).
Studies on CD8 T cells, neutrophils, NK and NKT cells have yielded similar results con-
cerning the eﬀects of OX40 ligation in promoting survival, diﬀerentiation and enhanced
eﬀector functions, but other than for CD8 T cells, literature is very sparse. Indeed, to
our knowledge, only one report showed staining for OX40 expression on NK cells and
this report was done in mice (34 ). Other studies in humans only implied a function
for OX40-OX40L interaction for NK cell function using blocking or agonistic antibodies
(35 ) (36 ) (37 ).
No other interaction partners for both OX40 and OX40L (also known as CD134L and
CD252) then with each other are known in humans and also in mice. Although inter-
stingly, in cats OX40 serves as binding receptor for the feline immunodeficiency virus
(38 ).
OX40L expression has been shown on APCs (B cells, macrophages, DCs), mast cells,
activated T cells and NK cells. It can furthermore be expressed on non-immune cells
such as bronchial smooth muscle cells, transformed cells or vascular endothelial cells
(31 ). OX40L, like OX40 is only expressed after induction. In 2004 two studies showed
that NK cells can induce the expression of OX40L after activation. Zingoni et al.
demonstrate that only combined cytokine and NKG2D or CD16 triggering induces
OX40L upregulation. In co-cultures with autologous CD4+ T cells, OX40L expressing
NK cells co-stimulated T cell proliferation and IL-2 or IFN-  production (39 ) (40 ).
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OX40/OX40L in the (pre)clinic Upregulation of OX40 and OX40L has been observed
in a variety of autoimmune diseases, such as rheumatoid arthritis (41 ), colitis, muliple
sclerosis and systemic lupus erythematosus. This sparked the development of OX40 and
OX40L antagonistic antibodies to ameliorate diseases. In mouse models of autoimmune
diseases treatment success with blocking/neutralizing antibodies showed both worsening
and amelioration of disease, depending on the model and treament conditions. Although
a human trial with humanized ↵-OX40L in asthma patients had no severe side eﬀects,
it was discontinued because of its ineﬃcacy (31 ).
In sharp contrast to this, OX40 agonist treatment for cancer patients shows a huge
potential for the advancement of immunotherapy.
It was shown that a large part of tumour-infiltrating CD4 T cells express OX40, estab-
lishing the prerequisit for using OX40 as a candidate for immunotherapy. Subsequently,
in pre-clinical animal studies OX40 agonist or OX40L-Fc treatment alone or in com-
bination with checkpoint blockade, radiation or cytokine treatment had a significant
survival benefit in almost all of the many studies performed (29 ).
The first human trial was conducted in 2013 with a mouse monoclonal ↵-human OX40
agonist. Treatment with only one dose led to the regression of metastasis in almost half
of the patients with advanced disease, while side-eﬀects were acceptable and milder,
when compared e.g. to ↵-CTLA4 checkpoint blockade. CD4 and CD8 T cells, but not
Tregs were expanded and activated in the tumour. Unfortunately, patients developed
anti-mouse antibodies and therefore the trial had to be stopped (36 ) (29 ). Several
other trials are being conducted or planned at the moment, including combination
trials using OX40 agonists and CTLA-4/ PD-1 blockade. Furthermore triple therapy
including e.g. KIR-blockade, which is also being investigated in clinical trials at the
moment, is envisaged for the near future.
Cytokine receptors
Cytokines and chemokines have an immense impact on all aspects of NK cell biology.
They are critical during NK cell development, they impact maturation/ diﬀerentiation,
migration/ homing, survival/ proliferation and eﬀector functions. More recently, cy-
tokine treatment of NK cells has even been shown to produce memory-like NK cells,
a feature that has previously thought to be restricted to the adaptive immune system
(42 ). The most important cytokine receptors for NK cells are described below.
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The common  -chain receptors NK cells depend heavily on a family of cytokines
which use di- or trimeric receptors in which one chain is the common  -chain (CD132).
The common  -chain cytokines include IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. All
receptors consist of a specific ↵-chain combined with the common  -chain, only IL-2R
and IL-15R are trimeric and furthermore include the IL-2R  (CD122). The common
 -chain is important for signalling in all receptors. It binds to Janus kinase (JAK)3
which activates downstream signal transducers and activators of transcriptions (STATs)
proteins by phosphorylation. Activated STATs dimerise, translocate to the nucleus and
activate transcription of target genes. Depending on the cytokine, diﬀerent STATs are
preferentially activated (IL-2, -7, -9 and -15 mostly activate STAT-5, IL-4 STAT-6 and
IL-21 STAT-1 and STAT-3) (43 ). The activation of diﬀerent STAT proteins by JAK3
is facilitated by the diﬀerential ability of inactive STAT proteins to bind to the specific
receptor ↵-chains. This leads to cytokine specific functions and NK cell activation.
Not only NK cells, but in fact all lymphocytes (T, B and NK cells) depend on common  -
chain/ JAK3 signalling. In humans and mice with genetic defects in either of the genes,
all lymphocytes are missing, causing the severe combined immune deficiency (SCID)
syndrome.
IL-4, IL-7 and IL-9 seem to have no or only little function in regulating peripheral human
NK cell responses. Of note, IL-7 might be important for the development of organ-
specific NK cells and IL-7R and IL-9R signalling is indispensable for the development
and survival of certain ILC populations (44 ). IL-21 has mainly co-stimulatory functions
and acts in concert with other cytokines to accelerate NK development, increase survival
and eﬀector functions, such as cytotoxicity and ADCC (45 ).
IL-2 and IL-15 are the most important cytokines for NK cell survival and proliferation.
Although their eﬀects on NK cells is similar, their expression and importance for NK
cells diﬀers.
IL-15, in contrast to IL-2 is most important during homoeostatic conditions. It is
indispensable for NK cell development and more potent than IL-2 in promoting NK
cell survival. The importance for NK maintenance is also mirrored in the production of
these cytokines. IL-15 is constitutively expressed by a variety of cell types of immune
and non-immune origin (monocytes, DCs, epithelial cells, stromal cells), while IL-2 is
primarily produced by CD4 T cells after TCR activation. However, IL-2 as well as
IL-15 treatment can stimulate NK cell eﬀector functions and proliferation.
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Furthermore, although both receptors use the IL-2R  chain and the common  -chain,
their ↵-chains and ligand binding vary greatly. In fact, IL-15 binding is quite unique.
While it can bind as a free cytokine to the trimeric receptor, most commonly it is
shuttled to the cell surface of the IL-15 expressing cell, already bound to the IL15R↵-
chain. IL15/IL15R↵ is then trans-presented to another cell expressing the   and  -chain
(46 ).
IL-2 can already bind with intermediate aﬃnity to the   and  -chain, but aﬃnity is
greatly increased if the IL-2R↵-chain (CD25) is incorporated into the receptor.
CD25, the high-aﬃnity IL-2R chain Expression of CD25 under normal conditions is
absent on CD56dim NK cells and T cells and only low levels are expressed on CD56bright
NK cells, but it is constitutively expressed on regulatory T cells (Tregs) (47 ). Because
of this and the fact that IL-2 is involved in T cell activation induced cell death, CD25
and IL-2 signalling also partake in immune regulation.
Various stimuli were shown to induce its expression on NK cells. For example stimula-
tion of activating NK cell receptors NKG2D, NKp30 and NKp46 with soluble MIC-A,
↵-NKp30 or ↵-NKp46 antibodies respectively, increased CD25 expression (48 ). En-
hanced percentage of CD25+ NK cells were also observed after Influenza vaccinations
(49 ). Furthermore CD25 is expressed on cytokine-stimulated NK cells, i.e. after IL-12
+ IL-15 + IL-18 treatment (50 ).
IL-12, IL-18 and the type I IFN receptors IL-12 signals via STAT-3, -4 and -5 and
can induce NK cytotoxicity and IFN-  and TNF-↵ production. Cytokine production
is mainly facilitated via STAT-4 signalling. Although it can act alone, IL-12 syner-
gises with other stimuli. For example IL-12 together with IL-2 or IL-15 trigger NK
IFN- , TNF-↵ and GM-CSF production. IL-12 also enhances tumor cell recognition
significantly (51 ) (52 ).
IL-18 does not signal through JAK-STAT, but has MyD88 and TRAF6 as adaptors
to activate MAPK and NF-B. IL-18R is, like the IL-12R constitutively expressed
on resting NK cells. IL-18 stimulation leads to minor NK proliferation which can be
drastically enhanced by IL-15 co-stimulation. Also IL-18 primed NK cells can produce
more IFN-  after subsequent IL-12 stimulation (52 ).
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IFN-↵ and -  can act on NK cells via the induction of JAK1 and diﬀerent STAT
proteins. STAT-1 and STAT-2 activation lead to increased cytotoxicity through an
upregulation of perforin and FasL, whereas STAT-4 activation increases IFN-  secretion.
Type I IFNs furthermore increase NK cell proliferation. The most potent producers of
type I IFNs are plasmacytoid dendritic cells upon virus encounter (51 ).
3.2.3 NK cell eﬀector functions
Cytotoxicity
NK cells have several modes through which they can induce death of a target cell. One
is through the production of TNFSF members, e.g. TRAIL and FasL, that activate
the death domain-containing TNFRs, which were discussed in chapter 3.2.2. The other
mechanism is via the release of cytotoxic granules, which mainly contain perforin and
the serine proteases granzyme A and B, as active agents. After engagement of a target
cell, an immunological synapse forms and the cytotoxic granules are released in close
proximity to the target cells. Perforin is then necessary to deliver the granzymes into
the target cell cytoplasms, but the exact mechanisms are still unclear. Once inside the
cytoplasm, granzymes can induce apoptosis via cleavage of pro-caspases, through the
induction of pro-apoptotic proteins or via the cleavage of mitochondrial and nuclear
proteins which eventually causes mitochondrial depolarisation and DNA fragmentation
(53 )(54 ).
Cytokine production
IFN-  - the NK signature cytokine The key cytokine produced by NK cells is without
a doubt the sole member of the type II IFNs: IFN- . IFN-  production, in contrast to
the members of the type I IFN family, IFN-↵ and - , which can be produced by virtually
any cell type upon viral infection, is restricted to immune cells. Besides NK cells, T cells
and NKT cells are also potent IFN-  producers. Induction of IFN-  in these cell types
is largely controlled by cytokines. After e.g. pathogen encounter macrophages produce
IL-12, which, in synergy with IL-18, potently induces IFN-  production by NK cells.
In turn, IFN-  is then one of the most important activating cytokines for macrophages
and stimulates many of its functions (55 ). In contrast to its limited production the
eﬀects of IFN-  are not limited to the immune system, as the IFN-  receptor is nearly
ubiquitously expressed (56 ).
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Although type I and type II IFNs are produced by diﬀerent cells and acting on diﬀerent
receptors, the intracellular signalling of type I and type II IFNs largely converge to
activate ISGs. The IFN- R, like many other cytokine receptors signals mainly via the
JAK-STAT pathway. The cytoplasmic tail binds to JAK1 and JAK2 which then facil-
itate STAT-1 phosphorylation. Phospho-STAT-1 dimers can then activate or suppress
transcription of IFN-  stimulated genes that contain the gamma Interferon activation
site (GAS) element. The eﬀects of the ISGs are manifold and embedded in a complex
interplay with other cytokine signals. Below are listed some of the actions of ISGs, but
this list can be expanded greatly, e.g. by the anti-proliferative and pro-apoptotic eﬀects
on cancer cells.
IFN-  in antigen-presentation ISGs induced by IFN-  include many that stimu-
late antigen-presentation in MHC-I and MHC-II complexes. Transcription of alter-
native proteasome components is initiated, which forms the immunoprotease and pro-
duces quantitively more and qualitatively better peptides to be loaded. Furthermore,
many proteins aiding antigen-loading are transcribed (e.g. transporter associated with
antigen-processing (TAP) or tapasin). It also directly upregulates chains of the MHC-I
and MHC-II complexes, even in cells that do not constitutively express MHC-II (55 ).
IFN-  in anti-microbial functions Macrophages are important eﬀector cells in the
defence against bacteria and parasites. IFN-  actives their direct phagocytic potential,
increases Fc RI to induce ADCC and increases complement and complement receptor
production. Also the production of microbicidal products, especially NO and reactive
oxygen species (ROS) production, is stimulated, which acts directly on the pathogens.
This is mediated via induction of the NADPH oxidase system and iNOS (55 ).
IFN-  antiviral functions Together with the type I ISGs, the IFN- -stimulated genes
can directly interact with all steps in the viral life cyle. One type II ISG is for exam-
ple the PKR kinase that binds the transcription initiation factor eIF-2↵, and thereby
inhibits cellular as well as viral protein translation, as almost all viruses use the cel-
lular transcription machinery (55 ). PKR activation also stimulates degradation of the
inhibitor of NF-B, which activates NF-B (56 ). ISGs interfere with viral entry, virus
translation and replication, the formation and release of viral particles through the
induction of a plethora of proteins.
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Other cytokines produced by NK cells Other pro-inflammatory cytokines that are
produced by NK cells are TNF-↵ and GM-CSF, the latter of which is important for the
cross-talk with monocytes/macrophages. To attract other immune cells to the site of
inflammation NK cells can produces the chemokines MIP-1↵, MIP-1 , RANTES and
IL-8. NK cells can as well produce anti-inflammatory cytokines like IL-5, IL-10 and
IL-13 (57 ).
3.2.4 NK cells in the liver
The liver has a quite specific immunological environment that has to balance tolerance
and inflammation carefully. On the one hand, the liver is constantly exposed to antigens
from bacteria and food that are drained into the liver from the gut via the portal vein, to
which the liver has to remain tolerant. This is promoted via a constant production of the
anti-inflammatory cytokines IL-10 and TGF- . The liver is therefore considered a more
immun privileged organ. But on the other hand, it has to eﬀectively fight pathogenic
threats. For the activation of potent NK cell responses in this context cross-talk with
Kupﬀer cells, the liver resident macrophages is very important (58 ).
The immune cells are primarily located in the sinusoids of the liver which spread through
the liver parenchyma, composed of hepatocytes. As the sinusoids are quite permeable,
contact between blood, immune cells and hepatocytes is guaranteed. The sinusoid
endothelial cells are separated from the hepatocytes via the space of Disse, a narrow
cleft where hepatic stellate cells reside (59 ).
The composition of immune cells is enriched in innate immune cells and especially in
NK cells. In fact, 30-40% of lymphocytes in the liver are NK cells, a number that
is only surpassed in the uterus, where around 50% of lymphocytes are NK cells. In
comparison, the percentage in blood is only 10-15%. Under pathological circumstances,
the percentage of NK cells in the liver can even reach up to 80 or 90%.
There are two types of NK cells present in the liver: the liver-resident NK cells and the
conventional NK cells, which are thought to only pass through the liver via the blood.
The liver-resident NK cells, as the name already suggests, rarely if ever leave the liver.
They are CD56bright and express chemokine receptors for CCL3, CCL5 and CXCL16,
chemokines which are produced by many cell types in the liver, including hepatocytes
and sinusoidal endothelial cells. They are also, like their mouse counterparts, positive
for the integrin CD49a and most likely depend on diﬀerent transcription factors than
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concentional NK cells (Tbet instead of Eomes). In fact, studies in mice have shown
the presence of hematopoietic precursor cells in the liver, that could replenish the liver-
resident NK cell pool directly within the organ. In humans further studies have to
provide inside into the origin and exact nature of the liver-resident NK cells and whether
they should be classified as a distinct ILC subset (58 ).
Functionally the liver-resident NK cells are potent producers of a many cytokines, in-
cluding IFN- , TNF-↵ and GM-CSF and they were shown, similar to mouse liver NK
cells, to possess a memory-like phenotype (59 ).
3.2.5 NK - monocyte/macrophage cross-talk
NK cells can directly recognise infected or transformed cells via their cell surface re-
ceptors and exert eﬀector functions. However, the nature and strength of their eﬀector
functions, survival, traﬃcking and other functions are strongly influenced by the sur-
rounding immunological milieu. Especially in the early phases of an immune response
the interaction with myeloid and dendritic cells is of great importance. Monocytes and
macrophages are, like NK cells, among the first cell types present at a site of inflam-
mation and they have the potential to aﬀect NK cells via cytokines or cell-cell-contact
dependent mechanisms.
The interaction of monocytes/macrophages and NK cells has been shown to stimulate
CD69 expression, a marker of NK cell activation and NK cell eﬀector functions in many
viral, bacterial and parasitic infections (60 ). This interaction is facilitated via diﬀerent
pathways.
Monocytes which are strongly stimulated with LPS or infected themselves with eg.
Mycobacterium tuberculosis upregulate NKG2D-Ligands (MIC-A/B and ULPBs) on
their surface. This cell-to-cell contact dependent interaction preferentially leads to the
killing of the monocytes to eliminate the pathogen in case they are directly infected and
is thought to prevent sepsis in case of overactivated monocytes. Like NKG2D, interac-
tion via NKp46 has also been primarily implicated in the direct killing of monocytes
(60 ). NKp30-ligand B7-H6 could be induced on inflammatory monocytes by LPS or
IL-1  stimulation and co-culture of B7-H6 expressing monocytes with autologous NK
cells also resulted in higher NK degranulation. Of note, IFN-  production was not
addressed in this study (61 ).
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However, low-dose LPS stimulation rather activates interaction via the 2B4-CD48 axis
which leads to NK cell cytokine production, rather than cytotoxicity (62 ). Therefore,
depending on the type and the strength of monocyte activation, diﬀerent cell-to-cell
contact dependent pathways can be activated leading to either NK cytotoxicity and
killing of monocytes or to NK cell cytokine production.
Beside the cell-cell-contact dependent monocyte - NK cell interaction, chemokines and
cytokines secreted by monocytes have a major impact on NK cell immunity.
After pathogen encounter monocytes and macrophages can produce pro-inflammatory
cytokines such as IL-12 and IL-18, whose impact on NK cells is described in chapter
3.2.2 and 3.2.3. IL-12 can be produced e.g. after infection with human cytomegalovirus
by inflammatory monocytes and was shown to play a role for the expansion of a subset
of NK cells carrying the NKG2C receptor which is thought to have adaptive features
(63 ).
Cytokine-production by Kupﬀer cells, the liver-resident macrophages was shown after
in vivo stimulation of human Kupﬀer cells with TLR-2, -3 or -4 ligands. In all con-
ditions, Kupﬀer cells produced pro-inflammatory IL-12, IL-18, TNF-↵, but also the
anti-inflammatory cytokine IL-10. TLR-2 stimulation was also able to induce IL-1  in
Kupﬀer cells.
3.3 Hepatitis C Virus
Hepatitis C Virus was discovered in 1989, after years of intensive research to find the
causative agent of the clinical non-A, non-B hepatitis (64 ).
HCV is a hepatotropic, enveloped virus. It is phylogenetically grouped into seven major
genotypes. Each genotype (1-7) can be further subdivided into many subgenotypes. In
western countries, the most prevalent subgenotypes are 1a, 1b, 2a, 2b, 3a, 4a and 6a.
Furthermore, due to the high error-rate of the viral polymerase, in every individual
many slightly diﬀerent viral genome, so called quasispecies, are present (65 ).
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3.3.1 Virology
Hepatitis C virus (HCV) is a single-stranded positive sense ss(+)RNA virus that belongs
to the genus hepacivirus of the flaviviridae family. Other well-known human pathogens
of the flaviviridae family are Dengue virus (DENV), West Nile Virus, Zikavirus and
Yellow Fever Virus, all of which are members of the flavivirus genus.
HCV is an enveloped virus. The virion consists of an icosahedral core, likely formed
from multiple copies of the core protein that encapsulates the viral RNA. The viral E1
and E2 glycoproteins are anchored in the core and the host cell derived double-layer
lipid membrane which forms the outer envelope of the virion. In the serum, the virions
have been observed either as free virions, bound to low-density lipoproteins (LDL) or
very low-density lipoproteins (VLDL) or bound to antibodies (66 ). The bound LDL and
VLDL particles and E2 play a role in the adhesion of the virion to the host cell by binding
to heparan sulfate proteoglycans (HSPG), low-density lipoprotein receptor (LDLR) and
scavenger receptor BI (SR-BI). Cellular entry is mediated by the tetraspanin CD81,
Occludin and Claudin 1. CD81 and Occludin further determine the species tropism for
HCV (65 ).
After viral entry the 9.6 kb genome is released into the cytoplasm, where it can directly
serve as a template for viral protein translation. It contains one single open reading
frame (ORF), flanked by 5’ and 3’ untranslated regions (UTRs). The ORF encodes one
long polyprotein, that is afterwards further processed by cellular and viral proteases
into 10 proteins: the three structural proteins E1, E2 and core and 7 non-structural
proteins p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B. A further protein using an
alternative reading frame has been described, but its function not well understood. It
has recently been implicated in activation of DCs and T cells (67 ).
The 5’UTR of the viral RNA contains an internal ribosomal entry site (IRES), where the
cellular ribosome can bind and translation being initiated, circumventing requirements
for normal cellular protein translation initiation, such as the 5’ cap (65 ).
The p7 protein is a transmembrane ion channel and is required for assembly and release
of the free virions, but its exact mechanisms of action are unknown. The NS2 protein
has cysteine protease functions and cleaves the polyprotein and the NS2-NS3 junction
and is furthermore required for virion assembly.
The NS3 protein forms a complex with its cofactor NS4A. The NS3 protein has two
domains, a protease and a helicase domain. The protease has been shown to be essential
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for establishment of chronic infection by cleavage of important host cell factors for
innate immune sensing, such as the RIG-I adaptor MAVS and TLR-3 adaptor TRIF.
The helicase domain functions in viral replication.
NS4A is a multifunctional protein that serves to organise the replication complex and
the formation of the membraneous web, the site of viral RNA replication (65 ).
NS5A is an indispensable part of the viral replication complex. Certain mutations in
the NS5A protein have been linked to the virus’ sensitivity to IFN, thus establishing a
role of NS5A for the host antiviral response (68 ).
NS5B is the viral RNA-dependent RNA polymerase. It transcribes the ss(+)-strand
RNA into a (-)-strand intermediate, which then serves as a template for the (+)-strand
RNA genome (65 ).
3.3.2 Epidemiology and Therapy
World-wide an estimated 185 million people are chronically infected with HCV. That
accounts for 2.5% of the world-population. Each year around 500 000 people die from
HCV-related liver diseases. HCV is distributed globally with the highest prevalences
in Central and East Asia and Africa (69 ). The seven genotypes have diﬀerent global
distributions. Genotype 1 is most common especially in developed countries, accounting
for almost 50% of all HCV infections (69 ). In Europe genotype 3 and increasingly
also genotype 4 are prevalent in drug-users, while genotype 2 is mostly seen in the
mediterranean region (70 ).
Transmission takes place from human to human via blood, unlike other members of the
flaviviridae, which are primarily spread via vectors (mosquitoes and ticks).
Until the establishment of HCV detection methods in the early 90s, blood transfusions
were a major route of infection. Nowadays, high risk-behaviour includes intravenous
drug usage and promiscuous sexual practices (71 ).
Acute infection is often asymptomatic and in many cases goes unnoticed. Those that
develop acute symptoms can have fever, nausea, joint pain and jaundice. Only around
15-45% of acutely infected patients can clear the infection spontaneously, the other 55-
85% will develop chronic infection. The probability for spontaneous clearance depends
on a variety of factors such as age, sex, co-infection with other viruses, host genetic
factors and viral genotype. Infection with HCV genoypte 1 is favorable for the outcome
compared to non-type 1 infection (72 ). The virus is also more likely to be cleared the
younger the patients are and when they are female (73 ).
29
3 Introduction
Interest in NK cells in the resolution of HCV infection was sparked, when in 2004,
Khakoo and colleagues found a genetic association between the expression of KIR2DL3
in patients homozygous for the HLA-C1 ligand and HCV clearance. They studied more
than thousand patients who were exposed to HCV. 685 of those developed chronic infec-
tion and 352 cleared the virus. They found that those patients whose NK cells expressed
the inhibitory KIR2DL3 homozygously on an HLA-C1/C1 background were more likely
to clear the virus spontaneously. Of note, when stratified in terms of route of infections,
this association only held true in patients with presumed low-dose viral inocculum, e.g.
after a needle-stick, suggesting contribution of NK cells is only eﬃcient when faced with
low viral loads (74 ). A similar correlation was found in exposed but uninfected injection
drug users. Their NK cells expressed higher levels of KIR2L3 than both drug users with
chronic and resolved infections and healthy donors. The same study also found NKG2A
less expressed on exposed, but uninfected drug users and could show that the ligand
for NKG2A, HLA-E was upregulated in HCV-infected livers (75 ). However, there are
also other studies which did not observe a correlation between KIR2DL3 and outcome
of infection, albeit with smaller sample sizes and diﬀerent patient cohorts (76 ) (77 )
(78 ).
At this time, the highest known impact for HCV outcome have number of single nu-
cleotide polymorphisms (SNPs) in the IFN-  (IL-28/29) gene locus. These IFN-  vari-
ants have been implicated in the spontaneous clearance (79 ) and in IFN-↵/Ribavirin
treatment induced clearance (80 ), but the mechanism through which the SNPs aﬀect
infection outcome are not well characterized.
HCV therapy Until 2011 the standard approved therapy for HCV was pegylated IFN-
↵/ Ribavirin (peg-IFN/RBV). However, only 40-50% of patients in Europe and North
America achieved sustained virological response (SVR) (no detectable HCV RNA 24
weeks after peg-IFN/RBV treatment). Of note, 99% of patients who achieve SVR
remain completely virus free. While peg-IFN/RBV therapy had low success rates for
genotype 1, other HCV genotypes especially genotype 2 achieved SVR rates of up to
80% (70 ). The low success rates combined with the severe side eﬀects of the therapy
demanded a high need for better treatment regimens. In 2011, the first direct acting
antivirals (DAAs) were approved - telaprevir and boceprevir, both targeting the viral
NS3/4A protease. These DAAs increased success rates, however, they still had to be
administered together with peg-IFN/RBV (70 ). This changed in 2015 when several new
DAA were approved for HCV, also in IFN-free therapies. DAA are grouped into four
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classes depending on their target and their structure: The NS3/4 protease inhibitors,
the NS5A inhibitors, the NS5B nucleoside polymerase inhibitors and the NS5B non-
nucleoside polymerase inhibitors. Diﬀerent combination treatments with several DAAs
have achieved very high SVR rates in infections with all genotypes. In some cases
almost 100% of patients achieved SVR (81 ).
3.3.3 Immunology
Innate immune response in hepatocytes
The primary sensing of HCV in hepatocytes is facilitated via RIG-I. Activation of
RIG-I recruits the adaptor MAVS which activates IRF3 and IRF7 transcription factors,
which amongst others induces the transcription of IFNs. Because of its important role
in the activation of the innate immune response, the virus has established mechanisms
to counteract the RIG-I pathway. The NS3-4A protease can cleave MAVS or release it
from the membrane, where it cannot function.
Recognition via the TLR3- TRIF pathway has also been reported, but most likely only
acts in combination with the RIG-I pathway. Some, but not all studies show that
NS3-4A can also cleave TRIF.
Furthermore many other viral proteins are also implicated to interfere with host immune
response, mainly with IFN signalling and its eﬀects.
After sensing of the virus, cytokine, especially IFN production is induced which in
turn induces ISGs. Interestingly, although ISG induction can be robustly seen in many
systems (humans, chimpanzee, cell culture), in most no or only very little type I IFNs
can be measured. However, type III IFNs (IFN- s) were significantly upregulated.
In fact, induction of ISGs might be primarily due to type III, and not type I IFN
induction by viral sensing and its autocrine and paracrine signalling in hepatocytes.
This could also be part of the explanation why SNPs in the type III IFN genetic region
are so stongly predictive of spontaneous clearance and treatment response to IFN-↵/
Ribavirin (65 ).
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Adaptive immune responses
B cells HCV stimulates the production of HCV-specific antibodies from B cells. Al-
though many antibodies are produced, the majority of those do not interfere with
infection by neutralising the virus. Those that do mainly bind to specific regions of the
E2 protein in the viral envelope. Most of these regions are important for binding to
the entry receptors. Several studies have confirmed that antibodies can help to prevent
infection of new host cells and support viral clearance. In one of them chimpanzees
received anti-HCV antibodies before infection and some protection could be observed.
Another study of patients from a unique cohort that was infected with HCV from one
single source showed that patients with early antibody production had a better chance
for viral clearance. Furthermore there seems to be selection pressure on the virus by B
cells, as viral escape mutants for neutralising antibodies can be found in patients. Some
of those mutants were even shown to use diﬀerent entry receptors.
Although antibodies can help fight infections, it is also known that they are not neces-
sary to do so, as agammaglobulinaemic patients who do not have mature B cells and
therefore no antibodies, can also clear the virus (65 ).
T cells Both CD4 and CD8 T cells are important for viral clearance and in chim-
panzees depletion of either leads to higher viral titres. The main eﬀector cells are the
CD8 T cells, nonetheless CD4 help is needed for CD8 T cell responses. Specifically in
the acute stage of infection, a strong HCV-specific CD4 T cells response is observed in
patients with viral clearance and certain MHC-II alleles are linked to better clearance.
But in the chronic stage virus-specific CD4 T cells are hardly detectable any more.
CD8 T cells are the main eﬀector cells against HCV. When they start to appear approx-
imately 6-8 weeks after infection, there is a marked drop in the viral titre accompanied
by a rise in liver enzymes. In particular their IFN-  production is essential for the anti-
viral response. Perforin, on the other hand is less important and virus-specific CD8 T
cells only contain little of it.
After the first drop in viral titre during acute infection, HCV quasispecies start to appear
that escape from CD8 T cells, those species become enriched are likely to be important
for the progression from acute to chronic phase. On top of the viral escape mutations
from CD8 T cells, T cell dysfunction is a major contributor to persistence of infection.
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CD8 T cells in chronically infected patients show an exhausted phenotype, low func-
tionality and expression of inhibitory molecules, like PD-1, CTLA-4, CD160, KLRG1,
Tim-3 and 2B4. Likewise, the few virus-specific CD4 T cells that are still present in
chronic infection, show a phenotype similar to that of CD8 T cells. T cell exhaustion
is however reversable, as successful DAA treatment can restore T cell function.
Another factor contributing to viral persistance is expansion of Tregs. In patient with
chronic infection a higher Treg frequency is observed than in patients with resolved
infection or healthy controls. Their main function is the suppression of CD8 T cells,
primarily through cell-cell contact. Two mechanisms are described that induce the
expansion of Tregs. First of all, infected hepatocytes produce TFG-  which supports
the generation of Tregs. And second of all, there is evidence that Tregs also expand
antigen-specifically, maybe even in response to the viral escape mutants. Consequently,
the appearance of viral escape mutants does not only protect the virus from CD8 T
cell responses, but at the same time induces Tregs and thereby further contributes to
establishment of chronic infection. Interestingly, some viral proteins are more potent
to induce Treg than others. For example immunisation with the Core protein induces
Treg expansion, whereas immunisation with NS3 induces eﬀector T cells.
Even though the expansion of Tregs supports the progression to chronic infection
and limits anti-viral responses, in chronic infection they also protect from severe im-
munopathology, as patients with high Treg levels also have lower liver enzymes in serum
(65 ).
3.3.4 Tools to study HCV
Cell culture systems
The Replicon System For years researchers tried to successfully propagate HCV in cell
culture without luck. Until in 1999, Lohmann and Bartenschlager, utilized a strategy
that has already been successful for other (+)-strand RNA viruses. They deleted genes
which are not neccessary for replication (E1, E2, core, p7 and NS2) from the genotype
1b consensus sequence (Con1) and inserted a selection marker (neomycin resistance),
creating a bicistronic HCV replicon. Electroporation of this in vitro transcribed vi-
ral RNA into Huh7 cells for the first time supported successful viral replication (82 ).
Replication was then further enhanced by two processes. First, the virus acquired cell-
culture adaptive mutations and second, highly permissive Huh7 subclones were selected.
33
3 Introduction
This was done by electroporating the replicon, selecting positive cells with G418 and
afterwards treating the cells with inhibitors or IFN to eliminate the virus. This way the
Huh7.5, Huh7.5.1 and the Huh7-Lunet cells were established, which all replicate HCV
with great eﬃciency.
The replicon-strategy and the cell-culture adaptive mutations were afterwards inte-
grated into other HCV strains and genotypes, which also allowed their replication in
Huh7 cells (65 ).
However, because all structural genes were missing and RNA has to be electroporated
into the cells, the Replicon system could only be used to study certain aspects of the
viral life cycle like replication, transcription or translation, but not attachment, entry,
virion assembly and egress.
HCV pseudoparticles: HCVpp To study the HCV entry process, in 2003 two groups
established retroviral pseudoparticles which display the E1 and E2 HCV envelope pro-
teins on their surface. These viral particles are produced by 293T cells after transfec-
tion with plasmids encoding human immunodeficiency virus (HIV) or murine leukemia
virus (MLV) gag-pol proteins and HCV E1 and E2 (83 ) (84 ). With the help of the
HCV pseudoparticles (HCVpp), many viral entry receptors could be identified.
Cell-culture derived HCV: HCVcc The same year, Kato et al. isolated a viral genotype
2a strain from a patient with fulminant hepatitis: japanese fulminant hepatitis 1 (JFH1)
that was able to replicate at high titers in Huh7 cell without the previously known cell-
culture adaptive mutations (85 ). Further investigations showed that this viral strain
was also replicating when the full-length viral genome was used and that viral particles
were formed. These were termed cell-culture derived HCV (HCVcc) and could, for the
first time, reproduce the complete viral life cycle.
Furthermore the JFH1 clone could not only replicate successfully in Huh7 cells and
their derivatives, but also in many other human hepatic cell lines, and even in human
non-hepatic and mouse cell lines (65 ).
One of the cell lines that was permissive for JFH1 (and also for Con1) was the Huh6
hepatoblastoma cell line, which was described by Windisch et al. in 2005 (86 ). The
replication of JFH1-replicons was sensitive to treatment with IFN-↵, similar to what
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is observed in Huh7 cells. But interestingly, IFN-  treatment, even at high concen-
trations, could not reduce viral levels in Huh6, whereas in Huh7 cells JFH1 RNA was
greatly diminished. Further micro-array analysis revealed, that many ISGs were diﬀer-
entially regulated in Huh6 and Huh7 cell lines and at least one of them had functional
consequences for the resistance to IFN-  (87 ).
Identification of host cell factors In 2005 a novel role for miRNAs was discovered,
when Jopling et al. described that miR-122 was necessary for HCV RNA replication by
binding to the 5’UTR. The binding site is conserved in the diﬀerent HCV genotypes,
making miR-122 a promising drug target for HCV infections with all genotypes (88 ).
In fact, a first clinical trial with miravirsen, a compound binding miR-122, was safe and
showed promising results (89 ).
Another major break-through for the study of HCV in cell cultures was made in 2015,
when Saeed et al. discovered that expression of the host cell factor SEC14L2 in Huh7.5
cells enables infection and replication of clinical HCV isolates. So far, only JFH1 was
able to replicate without cell-culture adaptions and infect cells from virions (90 ).
HCV in primary hepatocytes Attempts to infect primary human hepatocytes (PHH)
have been made, but with only moderate success. Replication in those cells is only very
low, on top, these cells are very hard to come by and diﬃcult to culture, as they loose
their diﬀerentiation status quite fast in culture (65 ). A bit better are primary fetal
human hepatocytes, as they are long-lived in cell-culture, but they also only support
low-level replication and have only been used in very few studies (91 ).
Animal models
Chimpanzee model The chimpanzee (pan troglodytes) was the first animal model for
HCV. It shares 98% genetic identity with humans and can be infected by non-adapted
clinical isolates by intravenous injection of infected patient sera. The first infections
of chimpanzees were already done a decade before HCV was even described, when it
was still known as the causative agent of non-A, non-B hepatitis. The infection course
is quite similar to humans. Many chimpanzees progress to chronic phase in which
hepatitis occurs (as measured by elevated liver enzyme levels), but they rarely develop
fibrosis, cirrhosis or hepatocellular carcinoma. Overall, HCV infection is less severe in
chimpanzees than in humans.
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The chimpanzee model has been an invaluable tool to study HCV, for testing HCV
treatments (such as the DAAs or the miR-122) and for vaccine research. But due to
ethical concerns, the use of chimpanzees is very restricted and even prohibited in many
countries. It also comes with high costs, all of which limits availability. Although it
remains the gold standard in HCV animal models, many of the studies can now be
performed in the constantly improving mouse models.
Mouse models In recent years several mouse models have been established that ad-
dress diﬀerent needs in the study of HCV.
The first mouse models were transgenic mice that expressed diﬀerent (only one, several
or even the whole HCV polyprotein) viral proteins. These mice showed diﬀerent liver
pathologies and immune activation, giving insights into the diﬀerent functions and
immunogenicities of the viral proteins (65 ).
Infection of mice with free virus was made possible in genetically humanised mouse
strains. Expression of human entry receptors in those mice overcame the species barrier
and allowed for infection of the mice with free virus. In this model viral entry could be
studied, as well as viral inhibitors and the mouse immune responses, as they show T
and B cell responses (92 ). Recent genetically humanised mice additionally expressing
host factors are now able to sustain chronic infection for more than a year and show
liver inflammation and fibrosis (93 ).
Eﬀorts have also been made to establish human-mouse chimeric models. The first mod-
els using immunodeficient mice to prevent graft rejection were the human liver chimeric
mice, in which human liver cells were engrafted. These were useful to study the viral life
cycle in human hepatocytes, but as they had no immune system, no immunological or
vaccine studies could be made and mice showed no liver injury (94 )(95 ). Subsequently
a human immunocompetent liver mouse model was established in which mice were en-
grafted with human liver and hematopoetic stem cells. In this system, mice show liver
inflammation and T cell responses to the virus (96 ).
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3.4 NK cells in Hepatitis C Virus infection
NK are important players, especially in the intial phase of the anti-HCV immune re-
sponse. The fact that NK cells do aﬀect the outcome of HCV infection was again
emphasised by the genetic association studies in 2004 already mentioned in chapter
3.3.2. It showed a strong association between the presence of KIR2DL3 on NK and the
spontaneous resolution of infection in donors that were homozygous for the KIR2DL3
binding MHC-I (C1/C1) (74 ). The same year, it was also shown that IFN-  pro-
duced by NK cells can in fact suppress replication of HCV RNA (97 ). Since then the
mechanisms of how NK cells are activated during HCV infection and their phenotype
and function during the diﬀerent stages of infection have been studied, although often
yielding quite controversial results.
3.4.1 Interaction of NK cells with HCV
Interaction of NK cells with HCV virions/ viral proteins Several early studies on
the role of NK cells in HCV infection addressed the direct interaction of NK cells with
HCV particles or with recombinant proteins.
In 1998 CD81 was identified as one of the binding receptors for HCV glycoprotein E2
(98 ) and subsequently it was shown that binding of E2 to CD81 on T cells serves as
a co-stimulatory signal (99 ). CD81 is also expressed on NK cells, but two reports
in 2002 showed that, in contrast to T cells, NK cells are inhibited by cross-linking
of CD81 by plate-bound E2 or ↵-CD81 antibodies (100 )(101 ). When HCVcc became
available Crotta et al. could confirm that also plate-bound HCV virions inhibited NK
IFN-  production via E2 - CD81 interaction. However, when free, non-plate-bound
virions were used, even at concentrations that by far exceeded concentrations naturally
occuring in infected livers or serum of patients, no eﬀect on NK cell function was
observed (102 ) (103 ). On the contrary, one group even showed that longer exposure
of HCVpp to isolated NK cells enhanced expression of activating receptors and NK
cytokine production (104 ).
Nevertheless, these conditions are highly artificial and virion concentrations and NK
interaction of this sort are very unlikely to occur in vivo.
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Interaction of NK cells with infected hepatocytes Infection of a host cell induces
many cellular stress responses that go along with upregulation of stress-related molecules
on the cell surface and/or release of cytokines and chemokines that can be detected by
NK cells.
One of the consequences of viral infection is altered MHC-I presentation. When Konan
et al. expressed individual non-structural HCV proteins or protein precursors in 293T or
Huh7 cells, they found that expression of the NS4A/B precursor protein alone, but also
expression of full-length HCV RNA inhibited the ER-to-Golgi transport and thereby
reduced antigen-presentation and MHC-I levels in Huh7 cells. (105 ). Likewise, Tardif
et al. showed lower MHC-I levels on HCV replicon-carrying Huh7 cells because of
aberrant folding due to ER stress caused by the virus (106 ). Herzer et al., on the
other hand, showed that expression of Core protein alone, but also expression of the
whole HCV polyprotein induced expression of MHC-I in HepG2, but not in Huh7 cells,
which were used by Konan and Tardif et al., attributing it to the mutant p53 status
of Huh7, but not HepG2 cells. They claim that the Core protein induces p53, which
upregulates TAP1 and thereby increases MHC-I surface levels. When Core protein
expressing HepG2 cells were used in a cytotoxicity assay against two NK cell lines, NK
cytotoxicity was impaired compared to control cells (107 ). The two former studies did
not address the eﬀect of MHC-I regulation on NK cell function in their system. Of
note, expression of the complete Core protein, but not E1, E2 or NS2 in HCV-protein
transgenic mice led to enhanced hepatocyte killing that could be abogated by depletion
of NK cells (108 ).
Although diﬀerences in MHC-I expression levels were observed in some studies, another
study, using the HCVcc infection system in Huh7.5 cells, showed no diﬀerence in MHC-I
levels between uninfected and infected hepatocytes (109 ).
Beside the classical MHC-I molecules, the non-classical MHC-I molecules, especially
HLA-E, are important for the development and function of NK cells. HLA-E is recog-
nised by the inhibitory receptor NKG2A as well as by the activating receptor NKG2C,
that is, however only expressed on a small subset of NK cells. HLA-E can be stabilised
on the surface of cell lines incubated with certain peptides derived from HCV Core pro-
tein. This led to reduced cytolytic activity of a NK cell line. Notably, elevated HLA-E
levels could also be shown on hepatocytes and Kupﬀer cells in patient livers (110 ).
Conflicting reports also exist about the induction of NKG2D ligands in HCV infection.
One study claims downregulation of NKG2D ligands, another shows higher expression
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of MIC proteins and third study observed no eﬀects (111 )(112 )(109 ). Diﬀerences are
likely due to the diﬀerent experimental systems and viral strains used.
On the side of the NK cell it was observed that contact with HCV-infected hepatoma
cells in vitro leads to the downregulation of activating receptors NKG2D and NKp30
which reduces the functional capacity of NK cells (113 ) (114 ).
Interaction of NK cells, accessory cells and infected hepatocytes Although NK
cells can be aﬀected possibly by the virus directly and by the infected hepatocytes,
the immunological milieu and the interaction with other immune cells have a major
influence on NK cell function. Especially monocytes/macrophages/Kupﬀer cells and
DCs greatly influence NK cells after viral RNA sensing.
DCs can activate NK cells by expressing MIC-A/B after stimulation. This upregulation
is inhibited in DCs from HCV-infected patients, resulting in less cytotoxic potential and
IFN-  production from NK cells after DC co-culture (115 ). Other NKG2D-Ligands,
namely ULPB-1, -2 and -3 were not upregulated on myeloid DCs after HCV infection
(116 ). Reversely, NK cells from HCV-infected patients also have a lower potential to
activate DCs. This might be because NK cells from patients express high amounts of
NKG2A that interacts with HLA-E on infected hepatocytes and induces NK production
of IL-10 and TFG- , which negatively regulates DC maturation and function (117 ).
The sensing of the virus by pDCs induces a strong type I IFN response and is dependent
on TLR-7 and, surprisingly, on cell-to-cell contact. Free virus does not activate pDCs,
but replicon-carrying hepatocytes that do not produce free viral particles can activate
pDC IFN-↵ production (118 ). In a follow-up study the same group could show that the
cell-to-cell contact dependent activation of pDCs is achieved via short-range transfer
of viral RNA in exosomes (119 ). 24 h co-culture of peripheral blood mononuclear cells
(PBMCs) with JFH1 infected Huh7.5 cells, performed by Zhang and colleagues, resulted
in enhanced IFN-  production by NK cells which could be almost completely abrogated
by depletion of pDCs and was due to pDC IFN-↵ production (120 ). Exogenous IFN-
↵ stimulation of NK cells has also been shown to upregulate TRAIL and TRAIL-
dependent killing of replicon-carrying Huh7.5 cells (121 ).
Besides DCs, monocytes have also been implicated in the activation of NK cells in HCV
infection. In fact, in the before mentioned study by Zhang et al., the authors could also
show a role for monocytes in NK cell IFN-  production. When they depleted pDC
from PBMC - Huh7.5/JFH1 co-cultures, NK cell IFN-  production was abrogated, but
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isolated NK cells and pDCs co-cultured with infected hepatoma cells did not result in
IFN-  production. Only NK + pDCs + monocytes in co-culture with Huh7.5/JFH1
led to NK eﬀector functions. The contribution of monocytes was attributed to their
production and trans-presentation of IL-15, as monocytes from infected co-cultures show
higher levels of IL-15R↵ and blocking of IL-15 reduced NK IFN-  production (120 ).
Production of IL-18 by monocytes in response to HCV infection was also implicated
in NK activation by Serti et al. in 2014. In 24 h PBMC, but not NK co-cultures with
Huh7/ JFH1 replicon cells, IFN-  production was higher than in uninfected cultures.
Depletion of monocytes and neutralisation of IL-18 abrogated the virus-dependent NK
activation. The authors showed that IL-18 is induced in monocytes via detection of the
HCV by the NALP3 inflammasome, as siRNA knock-down of NALP3 almost completely
inhibits IL-18 production (122 ).
Accessory cells have not only been shown to aid NK cells eﬀector functions, but can
also inhibit NK cells and thereby contribute to NK dysfunction and establishment of
chronic infection.
For example have Sène et al. shown that recombinant NS5A, as well as Huh7.5.1/JFH1
cell culture supernatants induce the production of the anti-inflammatory IL-10 and
subsequently that of TGF-  by monocytes which downregulates NKG2D on NK cells
and thereby limits their eﬀector potential (112 ).
Goh et al. showed that after 1-week co-culture of PBMCs with HCV-infected Huh7.5.1
cells the myeloid compartment was enriched in myeloid-derived suppressor cells (MDSCs).
Subsequent co-culture of the isolated CD33 + myeloid cells with autologous IL-12/18
stimulated NK cells for 2 days resulted in lower NK IFN-  production. It is notewor-
thy that the percentage of IFN-  producing NK cells was not significantly reduced and
reduction in the per cell IFN-  production (MFI) was only slightly, albeit significantly
reduced (123 ).
3.4.2 NK cell responses during infection
The natural course of Hepatitis C Virus infection can be divided into three phases: first
the incubation time where no viremia is present, followed by the acute phase in which
the innate and the adaptive immune system is strongly activated and the virus tries to
escape from its attack. If the immune system fails to control acute infection, around
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6 month after infection the chronic phase is established that can last for decades if
infection is not treated.
NK cells have been implicated as important players in all phases of HCV infection.
However, many of the results are ambiguous. One problem of many of the HCV patient
studies which makes them hard to compare to each other and to reproduce findings
are the diﬀerent cohorts that are studied and the often small sample sizes, especially
in the acute phase of infection. Diﬀerences in viral genotype, patient ethnicity, which
has a great influence on HCV outcome, age, sex, route of infection, but also diﬀer-
ences in study design and choice of control groups likely all contribute to the observed
discrepancies regarding NK cells in HCV infection.
NK cells in acute infection
To study NK cells during acute infection is not an easy task, because relevant patient
cohorts are hard to identify, mainly because acute infection is clinically often silent and
therefore remains unnoticed. Most studies were therefore conducted on high risk groups
such as intravenous drug users (IDUs) and exposed healthcare workers, but those have
generally very small sample sizes.
Several studies have followed IDUs who were exposed to HCV and either remained
uninfected (exposed-uninfected) or progressed to acute infection. Those that progressed
to acute infection, can furthermore be classified in two groups, one that subsequently
resolved the virus (acute-resolving) and one that progressed to chronic disease (acute-
chronic). Reports about the phenotype and function of NK cells in exposed-uninfected
individuals vary greatly. For example, some reports say that NKp30 expression is
higher on exposed-uninfected NK cells (124 )(125 ), while another claims that there is no
diﬀerence in NKp30 levels (126 ). Alter et al. observed that in patients that progressed
to chonic disease NKp30 levels on NK cells were in fact higher than in patients with
acute-resolving infection.(127 )
Reports on NK function are equally conflicting. Degranulation of NK cells against stan-
dard targets (K562) or directly ex vivo was shown to be higher in exposed-uninfected
individuals in one study (124 ), but lower in others (126 ) (125 ). Likewise IFN-  pro-
duction was reported to be higher (125 ), but also unchanged (124 ) (126 ) in exposed-
uninfected compared to exposed-infected individuals. Although when compared to
healthy controls IFN-  production was lower in all exposed groups (126 ).
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One study followed 12 health care workers who had been exposed to HCV by acci-
dental needle sticks. 11 out of 12 remained uninfected and those showed a strong NK
cell response early in infections. IFN- , degranulation, TRAIL, NKp44 and NKG2A
expression were all induced shortly after HCV exposure when compared to follow-up,
after virus clearance. Furthermore NK activation was seen around 4 weeks earlier than
in the person that became infected and magnitude of NK degranulation correlated with
the subsequent strength of T cell responses (128 ).
When comparing acute-resolving vs. acute-chronic infection instead of exposed-uninfected
vs infected, it was observed that no matter the outcome, NK IFN-  production, degran-
ulation and NKG2D expression are higher in acute infected NK cells than in healthy
individuals (129 ).
NK cells in chronic infection
Studies on NK cells in chronic infection are more numerous and with bigger sample
sizes and some have also had access to intrahepatic, not only peripheral NK cells, but
unfortunately this does not make their findings less conflicting than those from the acute
phase of infection. In general it has to be taken into consideration that the immune
system in the chronic phase of infection has already failed to clear the virus and that it
is now acting in a state of chronic inflammation which is known to cause dysfunction or
anergy of leukocytes. It is therefore hard to distinguish whether changes in phenotype
or function are the cause or the consequence of chronic infection (130 ).
In terms of NK receptor expression during chronic infection, studies have reported
both increase and decrease for many important NK receptors, such as NKG2D, NKp46
or NKp30 (131 ). However, in all that discrepancy, there is one receptor - NKG2A
- which has consistently been reported to be upregulated in chronic HCV patients
(117 )(132 )(133 ). Accordingly the ligand HLA-E also seems to be upregulated on in-
fected hepatocytes as already mentioned in chapter 3.4.1 (110 )(132 ). The relevance of
this regulation have yet to be fully determined. Another NK marker that received more
substantial attention was NKp46. Most studies have reported an increase in NKp46
on peripheral and intrahepatic NK cells in chronic HCV infection. This NKp46high
NK cell subset shows a strong cytotoxic and cytokine producing potential and can kill
infected hepatocytes (134 ). This is substantiated by the finding that high number of
intrahepatic NKp46+ cells correlate with higher liver inflammation scores (135 ).
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3.4 NK cells in Hepatitis C Virus infection
Functionally most studies report that NK cells tend to increase cytotoxicity and de-
crease IFN-  production during HCV. Mechanistical studies attribute this functional
scewing to consistent exposure to IFN-↵ in the chronically inflammed liver which in-
duced STAT-1 over STAT-4 phosphorylation and thereby favors NK cytotoxicity over
IFN-  production (136 )(137 ). This could contribute to the persistance of virus, as
IFN-  is thought to be more important for the anti-viral response than cytotoxicity
and at the same time contribute to live pathology. On the other hand, NK cells and
especially the NKp46high NK cells, have also been shown kill hepatic stellate cells and
thereby contribute to reducing liver fibrosis. A further mechanisms to eliminate hepatic
stellate cells is via NK expression of TRAIL (134 )(138 ).
Of note, although conventional CD56+CD3  NK cells are pushed towards cytotoxi-
city, there is a CD56  NK cells subset, defined as CD14 , CD3 , CD19 , CD56 ,
CD16bright, emerging during chronic HCV, but also during many other pathogenic cir-
cumstances, that has shown to be highly dysfunctional (139 ).
Taken together, NK cell phenotype and functions are altered during chronic infection,
a highly dysfunctional CD56  NK subset appears and NK cells can contribute to liver
pathology, but also to amelioration of fibrosis.
NK cells in treatment
For a long time IFN-↵/Ribavirin treatment was, and in many parts of the world still
is, the standard HCV therapy. But in the last few years the DAAs have revolutionised
treatment, achieving almost 100% success rates for many viral genotypes.
As IFN-↵ is a potent activator of NK cells, many studies have addressed NK function
during HCV therapy and studied the eﬀect of IFN-↵ on NK cells in regard to their anti-
HCV functions. Here, the majority of papers is in accordance that a strong and early
NK cells response, as expressed for example in higher expression of activation marker
CD69, predicts high chances of achieving SVR. IFN-↵ activates STAT1 phosphory-
lation and promotes NK cell cytotoxicity which coincides with rising alanine amino-
transferase (ALT) levels as early as 24 h after treatment (131 ). It furthermore induces
TRAIL expression on NK cells which is inversely correlated with HCV-RNA levels, sug-
gesting TRAIL-mediated killing as an additional mechanism to the granzyme/perforin-
mediated killing to eliminate virus-infected cells during therapy (121 ).
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3 Introduction
NK cells were also studied during IFN-free DAA therapy, although the DAAs do not
act directly on the immune system this setting provides a chance to study the normal-
ization of immune cells when the driver for a chronic infection, in this case the virus, is
elminiated.
After successful DAA therapy, NK cell phenotype quickly normalises again, revealing
that the dysfunction and distorted phenotype during the chronic infection did most
likely not induce permanent changes in the NK cell subset (140 ).
Antigen-specific CD8 T cells also regain normal phenotype and function after successful
DAA therapy but interestingly mucosal-associated invariant T cells (MAITs) seem to
be irreversibly altered during HCV infection, the exact mechanism however remains to
be determined (141 ).
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4 Aim of this study
HCV infection is a major global health problem and incidences of HCV-related liver
diseases are predicted to rise over the next years, despite new eﬀective treatments.
Upon infection a minority of patients can spontaneously clear the virus, while most
progress to chronic infection. Furthermore response to IFN-↵/Ribavirin treatment is
also only eﬀective in some of the treated patients. The exact underlying mechanisms are
still unclear, but several immune system-related factors have been implicated. Among
those genetic associations with NK cell receptors.
However, studies on the phenotype of NK cells in HCV infected individuals are highly
controversial and mechanistic insights into the interaction of virus-infected cells and
NK cells are rare.
In the present study, we therefore wanted to investigate mechanisms of how HCV-
replicating hepatocytes interact with NK cells directly and in the context of the im-
munological environment.
Results from this study are potentially relevant for therapeutic intervention strategies
that increase NK cell functionality and anti-viral immune responses against HCV.
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5.1 Material
5.1.1 Chemicals
Table 5.1: Chemicals
Chemical Company
Antibody diluent Dako Cytomation
Bafilomycin Sigma-Aldrich
 -mercaptoethanol Sigma-Aldrich
Chloroform Sigma-Aldrich
DTT Sigma-Aldrich
EDTA Ambion
Ethanol Sigma-Aldrich
Fluoromount-GTM eBioscience
GW4869 Sigma-Aldrich
H2O2 Sigma-Aldrich
Isopropanol Sigma-Aldrich
Mayer hemalum solution Applichem
Methanol Sigma-Aldrich
Nuclease-free water Ambion
nucleoside triphosphates (NTPs) ChemCyte
Phenol Sigma-Aldrich
RNasin Promega
Spermidin Sigma-Aldrich
Tween20 Sigma-Aldrich
Xylol Sigma-Aldrich
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5.1.2 Enzymes
Table 5.2: Enzymes
Enzyme Company
MluI restiction enzyme New England Biolabs
RNase-free DNase Promega
T7 RNA polymerase Promega
5.1.3 Cell culture products
Table 5.3: Cell culture products
Product Company
ATP ChemCyte
Biocoll separating solution Biochrom
Dimethyl sulphoxide DMSO Hybri-Max Sigma-Aldrich
Dulbecco’s modified Eagle’s Medium Sigma-Aldrich
Dulbecco’s phosphate buﬀered saline (PBS) Sigma-Aldrich
Fetal Calf Serum gibco
Geneticin (G418) gibco
Glutathion Sigma-Aldrich
GolgiPlug BD Biosciences
GolgiSTOP BD Biosciences
HEPES buﬀer solution 1M PAA
Hygromycin B invitrogen
IL-12 Peprotech
IL-15 Peprotech
IL-2 NIH
LD Columns Miltenyi Biotech
L-Glutamin 200mM (100x) gibco
LS Columns Miltenyi Biotech
MEM NEAA (100x) gibco
Penicillin/Streptomycin Sigma-Aldrich
Trypsin-EDTA Solution Sigma-Aldrich
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5.1.4 Kits
Table 5.4: Kits
Product Company
CD14 microbeads human Miltenyi Biotech
CD3 microbeads human Miltenyi Biotech
Foxp3 / Transcription Factor Staining Buﬀer Set eBioscience
human IL-18 ELISA Kit R&D
Light-Cycler 480 SYBR Green I Master Kit Roche
MACSplex human Cytokine 12 Kit Miltenyi Biotech
NK cell isolation kit human Miltenyi Biotech
NucleoSpin R  Gel and PCR Clean up Kit Macherey Nagel
ProtoScript M-MuLV First Strand Synthesis Kit NEB
RNeasy Mini Kit Qiagen
TURBO DNase Kit Ambion
VECTASTAIN Elite ABC Kit (Mouse IgG) Vector Laboratories
5.1.5 Cell lines
Table 5.5: Cell lines
Cell line Cell type Medium
Huh6 hepatoblastoma DMEM, 10%FCS, 1%PS, NEA
Huh6 cure hepatoblastoma DMEM, 10%FCS, 1%PS, NEA
Huh6-sgJFH1 hepatoblastoma DMEM, 10%FCS, 1%PS, NEA,
500µg/ml G418
Huh7 hepatocellular carcinoma DMEM, 10%FCS, 1%PS, NEA
Huh7 9-13 hepatocellular carcinoma DMEM, 10%FCS, 1%PS, NEA,
1mg/ml G418
Huh6-DENV hepatoblastoma DMEM, 10%FCS, 1%PS, NEA,
75µg/ml hygromycin
K562 myelogenous leukemia RPMI, 10%FCS, 1%PS
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5.1.6 Antibodies
Table 5.6: Antibodies for flow-cytometry I
Antigen Clone Company
4-1BBL 282220 R&D Systems
Axl 108724 R&D Systems
B7-H6 1.18 G.Moldenhauer, DKFZ
CD107a H4A3 BioLegend
CD112 TU27 BioLegend
CD127 A019D5 BioLegend
CD14 HCD14 BioLegend
CD155 SKII.4 BioLegend
CD158a/h HP-MA4 BioLegend
CD158b DX27 BioLegend
CD25 BC96 BioLegend
CD28 CD28.2 BioLegend
CD3 SK7 BioLegend
CD38 HIT2 BioLegend
CD40 5D3 BioLegend
CD56 HCD56 BioLegend
CD57 HCD57 BioLegend
CD80 2D10 BioLegend
CD86 IT2.2 BioLegend
CD94 HP-3D9 BD Bection Dickinson
CD96 NK92.39 BioLegend
DNAM-1 DX11 BioLegend
Dtk/ Tyro-3 96201 R&D Systems
Gal-9 9M1-3 BioLegend
GITR 621 BioLegend
HVEM 00122 BioLegend
IFN-  B27 BioLegend
MIC-A AMO-1 Bamomab
MIC-B M369 non-commercial
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Table 5.7: Antibodies for flow-cytometry II
Antigen Clone Company
NKG2A REA110 Miltenyi Biotec GmbH
NKG2C 134591 R&D Systems
NKG2D 1D11 BioLegend
NKp30 P30-15 BioLegend
NKp30-Fc - R&D Systems
NKp44 P44-8 BioLegend
NKp44-Fc - R&D Systems
NKp80 5D12 BioLegend
OX40 Ber-ACT35 BioLegend
OX40L 11C3.1 BioLegend
pan-MHC class I w6/32 BioLegend
PD-L1 MIH1 BD Becton Dickinson
TIGIT MBSA43 eBioscience
TIM-3 344823 R&D Systems
ULBP-1 M291 non-commercial
ULBP-2 M311 non-commercial
ULBP-3 M550 non-commercial
ULBP-4 M479 non-commercial
Table 5.8: Secondary antibodies for flow-cytometry
Secondary antibody Company
goat ↵-human-Fc Jackson ImmunoResearch Laboratories
goat ↵-mouse-Fc Dianova
Table 5.9: Isotype control antibodies for flow cytometry
Antigen Clone Company
CD99-Fc - R&D Systems
mIgG1 MOPC-21 BioLegend
mIgG2a MOPC-173 BioLegend
mIgG2b MPC11 BioLegend
rIgG2b 10H5 eBioscience
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Table 5.10: Neutralising Antibodies / Reagents
Antigen Clone Company
GM-GSF (LEAF) BVD2-23B6 BioLegend
IL-18 BPa Fc - R&D Systems
IL-2 (LEAF) MQ1-17H12 BioLegend
IL-6 (LEAF) MQ2-13A5 BioLegend
OX40L MM0505-8S23 antikoerper-online
OX40L Oxelumab R4930 absolute antibody
Table 5.11: Antibodies for Immunohistochemistry
Antigen Clone Company
msOX40L MM0505-8S23 abcam
msIgG1 MOPC-21 BioLegend
horse ↵ms-biotin - Vector Laboratories
5.1.7 Cell dyes
Table 5.12: Cell dyes
Bye Company
7-AAD BioLegend
CFSE Sigma-Aldrich
Zombie AquaTM BioLegend
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5.1.8 Oligonucleotide RT-qPCR Primers
Primer Sequence 5’ - 3’
HCV RNA gt2a forward TCTGCGGAACCGGTGAGTA
HCV RNA gt2a reverse GGGCATAGAGTGGGTTTATCCA
ULBP-1 forward AAGAATTTTTGATGTACTGGGAACAA
ULBP-1 reverse ATGAAGCAGAGGAAGATGATGAGAA
ULBP-2 forward GATGGCTTGAGGACTTCTTGATG
ULBP-2 reverse TGGGTTGTGCCTGAGGACAT
MIC-B forward TGCAGAAACTACAGCGATATCTGAA
MIC-B reverse TGCATGTCACGGTGATGTTG
B7-H6 forward TTATTCCCAACCCCTCAACA
B7-H6 reverse AGACACAATGGCTCCAGGTC
CD155 forward TCAACGCCAAGTCATCCTCC
CD155 reverse CCAAGAGTTCAAGACCAGCC
NKp44L forward ATCTGGTTTCGGACGGACTG
NKp44L reverse ATTGCTTCCCACAAAGTTGCC
CD54 forward TGGTAGCAGCCGCAGTCATA
CD54 reverse CTCCTTCCTCTTGGCTTAGT
GAPDH forward GCAAATTCCATGGCACCGT
GAPDH reverse TCGCCCCACTTGATTTTGG
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5.2 Methods
5.2.1 Generation of Replicon cell lines
In vitro RNA transcription of subgenomic RNAs In vitro transcripts were generated
by using 10µg DNA from the plasmids in figure 5.1A)-C) that had been linearized by
1 h digestion with the restriction enzyme MluI. DNA was purified using NucleoSpin R 
Gels and PCR Clean up Kit. In vitro transcription reaction mixtures (final volume
100µl) contained 80mM HEPES (pH 7.5), 12mM MgCl2, 2mM spermidine, 40mM
dithiothreitol (DTT), 3.125mM of each nucleoside triphosphate, 1U of RNasin/µl,
0.1µg of plasmid DNA/µl, and 0.6U of T7 RNA polymerase/µl. After 2 h incubation
at 37 C, 0.3U of T7 RNA polymerase/µl of reaction mixture was added and the reaction
mixture was incubated over night at 37 C. 1.2U of RNase-free DNase per µg of plasmid
DNA was added to terminate transcription and incubated for 30min at 37 C. RNA was
extracted with acidic phenol and chloroform, precipitated with isopropanol at room
temperature and dissolved in RNase-free water.
Electroporation of subgenomic RNAs Huh6 or Huh7 cells were trypsinised and
washed with PBS and resuspended at single-cell suspensions at a concentration of
1.5x107 cells/ml in Cytomix (described in (142 )) supplemented with 2mM ATP and
5mM glutathione for subsequent electroporation. 2.5 µg in vitro RNA transcripts were
mixed with 100µl cell suspension and transfected by electroporation using the Bio-Rad
GenePulser system with 0.2 cm gap cuvette at 500µF and 166V. Cells were immedi-
ately diluted in DMEM + 10% FCS + 1x L-Glutamin + 1% Penicillin/Streptomycin
and seeded.
Selection and curing of transfected cells 2 days post electroporation 500µg/ml
(Huh6-sgJFH1) or 1mg/ml (Huh7 9-13) G418 (Geneticin) or 75µg/ml Hygromycin
(Huh6-sgDENV) was added to the medium to select cells carrying the replicon. After
the selection process was completed, some of the cells were treated with viral inhibitors
(100 nm BMS-553 and 5µM Telaprevir) for 2 weeks to cure cells from viral RNA. Elim-
ination of viral RNA was confirmed by RT-qPCR. Culture medium of replicon cell lines
was always supplemented with the above mentioned antibiotics.
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Fig. 5.1: Plasmids containing the HCV and DENV replicons Plasmid of the replicons were
kindly provided by Ralf Bartenschlager. A)Plasmid map of the sgJFH-1 replicon. B) Plasmid map of
the sg9-13 replicon. C) Plasmid map of the sgDENV replicon.
5.2.2 Real Time Quantitative Polymerase Chain Reaction (RT-qPCR)
RNA isolation 1x106 cells were harvested and washed with PBS for RNA lysis using
the RNease Mini Kit. The cell pellet was resuspended in 350µl RLT buﬀer supple-
mented with 3,5µl  -mercaptoethanol. Samples were homogenized by adding them to
QIA shredder columns and centrifugation for 2min at full speed. To the flow-through
350µl 70% ethanol was added and the whole lysate added onto RNeasy spin columns,
which were centrifuged at full speed for 15 s. Columns were washed three times: 1x
with 700µl of buﬀer RW1 and 2x with 500µl buﬀer RPE, each time centrifugation was
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15 s at full speed. Membrane was dried by centrifuation for 2min at full speed. RNA
was eluted from the column by adding 50µl nuclease-free water and centrifugated for
2min.
DNase digestion DNase was digested using the TURBO DNase Kit. 10µg of isolated
RNA + 5µl 10xTURBO buﬀer + 1µl DNase + necessary amount of nuclease-free water
to reach 50µl were incubated at 37 C for 30min. DNase was inactivated by adding 5µl
of DNase inactivation reagent and incubation at room temperature for 2min. RNA
sample was centrifuged and supernatant transferred to a fresh tube.
First strand cDNA synthesis 5µl of the DNase treated-RNA were incubated with
3µl of random primer provided in the ProtoScript M-MuLV First Strand Synthesis Kit
at 70 C for 5min to denature RNA. To the reaction 10µl M-MuLV Reaction Mix and
2µl nuclease-free water was added and first strand cDNA synthesis carried out at 42 C
for 1 h. Enzyme was activated by incubation of the reaction at 80 C for 5min.
RT-qPCR The 20µl cDNA reaction was diluted by adding 80µl of nuclease-free wa-
ter. 2.5µl of diluted cDNA were added per well to LightCycler480 Mulitwell plates
together with 1.5µl nuclease-free water, 0.5µl forward and 0.5µl reverse primers in a
final concentration of 0.5µM and 5µl of Master Mix from the LightCycler 480 SYBR
Green I Master Kit. Each reaction was performed in triplicates. As negative control
nuclease-free water was used instead of cDNA. The plate was sealted with foil, shortly
centrifuged and the reaction run with the following PCR program on the Roche Light-
Cycler 480:
Preincubation 95 C 7min
Amplification Denaturation 95 C 10 s
Annealing 60 C 15 s
Extension 72 C 20 s
45 cycles
Melting curves 95 C 5 s
65 C 60 s
Cooling 40 C 10 s
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5.2.3 Flow cytometry staining and analysis
Extracellular staining For extracellular staining of cells for flow cytometric analysis,
cells were harvested with Trypsin and washed with PBS. Between 1x105 and 1x106 cells
were transferred into 96-well U-bottom plates and resuspendend in 25µl FACS buﬀer
(PBS + 3% FCS + 0.05% NaN3) containing all primary antibodies, isotypes or fusion
proteins. Cells were incubated for 30min on ice in the dark and then washed twice with
FACS buﬀer. In case of unconjugated primary antibodies, fluorophor-conjugated 2nd
antibodies were added in 25µl FACS buﬀer for 30min on ice in the dark, followed by
two washing steps using FACS buﬀer. For staining of dead cells, 7-AAD dye was added
to the cells for 5min diluted 1:50 in FACS buﬀer followed by two washing steps using
FACS buﬀer before analysis. If cells were fixed for intracellular staining, AquaZombie
was used for live/dead cell discrimination instead of 7-AAD. For this, AquaZombie dye
was diluted 1:250 in PBS and 25µl added to the cells for 10min on ice and then 25µl of
primary antibodies diluted in PBS (concentration adjusted for a final volume of 50µl)
and directly added to the cells for 30min without washing.
Intracellular staining For intracellular staining cells were fixed and permeabilised after
AquaZombie and extracellular staining using the Foxp3 / Transcription Factor Staining
Buﬀer Set from eBioscience. Fixation/Permeabilization concentrate was diluted 1:4,
25µl added to the cells and incubated for 30min on ice. Primary antibodies were
diluted in Permeabilization buﬀer at the titrated concentrations and 25µl added to
cells for 30min on ice. Afterwards cells were washed twice with Permeabilization buﬀer
and once with FACS buﬀer before analysis.
Cells were analysed on a BD FACS CaliburTM or a BD FACS Canto IITM . For com-
pensation, single stainings of each used fluorophor were recorded. Data was analysed
using the FlowJo9.9.4 (Treestar) software.
CFSE labelling of PBMCs PBMCs were adjusted to 1x107 cells/ml in PBS and 3.3µl
of 300µM CFSE/ml added while shaking the cells. Cells were incubated for 10min at
37 C in the incubator and then washed twice with complete DMEM medium.
57
5 Material & Methods
5.2.4 Isolation of PBMCs and co-culture set-up
Isolation of PBMCs from human peripheral blood Buﬀy coats were ordered from the
Blutbank Mannheim and diluted 1:4 with pre-warmed PBS. 15ml of Bicoll separating
solution was added to the bottom of a 50ml falcon and carefully overlaid with 35ml
of the diluted buﬀy coat. Tubes were centrifuged at lowest acceleration and without
brakes for 30min at 1800 rpm. The cell layer was removed and cells washed 4 times
with PBS.
Co-culture set-up The isolated cells were in some cases stained with CFSE, treated
with neutralising agents and/or inhibitor GW4869 before co-culture. For neutralization
cells were spun down and the pellet incubated for 20min with the appropriate amount
of antibody or isotype control (↵GM-CSF: 7.5µg/ml, ↵IL-6: 5µg/ml, both ↵OX40L:
10µg/ml, IL-18 BPa: 2.5µg/ml, ↵IL-2: 20µg/ml). Afterwards appropriate amount
of medium to reach the final antibody and cell concentration (2x106 cells/ml) was
added. Exosome-inhibitor GW4869 or equivalent amounts of the solvent DMSO was
added to a final concentration of 10µM. 2x106 PBMCs, NK cells or PBMCs depleted of
CD3+ or CD14+ cells in 1ml complete DMEM were added to 24-well plates containing
the hepatocytes which were seeded one day before at concentrations to reach 70-80%
confluence at the start of co-culture. Cells were then incubated for up to 6 days without
medium exchange at 37 C, 5%CO2. Neutralising reagents were again added at day 4.
For Transwell experiments, 4x105 isolated CD14+ cells in 1ml complete DMEMmedium
were added to the bottom well and 4x105 PBMCs depleted of CD14+ cells added in
200µl into the Transwell insert.
5.2.5 Magnetic-activated cell sorting (MACS)
Isolation of NK cells and CD14+ cells and depletion of CD3+ and CD14+ cells was
done using cell isolation kits (Miltenyi Biotech) according to manufacturer’s protocol,
although only 70% of the indicated antibody solutions was used. Purity of isolated cells
and depletion eﬃcacy, as determined by flow cytometry staining, was in all cases >95%,
except for depletion of CD3+ cells, where eﬃcacy was only 80-85%.
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5.2.6 Functional assays
Cell restimulation for intracellular IFN-  staining
After the co-cultures PBMCs were harvested and washed with complete DMEMmedium.
Cells were resuspended in fresh medium containing 5µg/ml IL-12 and 50µg/ml IL-15.
PBMCs harvested from one well of the 24-well plate were distributed to 3 wells of a
96-well plate (200µl each) and incubated at 37 C for 18 h. For the last 4 h 50µl of
1:166.66 in medium diluted GolgiPlug (containing Brefeldin A) was added to the wells.
Afterwards cells were washed and stained for flow cytometric analysis.
CD107a degranulation assay
After the diﬀerent co-cultures (Huh6, Huh6 cure, Huh6-sgJFH1 and PBMC only)
PBMCs were harvested, washed with complete DMEM medium and adjusted to 1x106
cells/ml. Target cells (Huh6, Huh6 cure, Huh6-sgJFH1 and K562) were also harvested
by trypsinisation and also adjusted to 1x106 cells/ml. 100µl of PBMCs (eﬀector cells)
and target cells were added to a 96-well V-bottom plate (E:T ratio = 1:1). As a con-
trol eﬀector cells were cultured alone in 200µl final volume. 1µl/well CD107a-FITC
antibody was added to each well at the beginning of the assay and after 1 h 0.5µl/well
GolgiSTOP (containing Monensin) was added. After an additional 4 h cells were har-
vested and stained for CD3, CD56 and 7-AAD.
5.2.7 Cytokine measurement
MACSplex For determination of cytokines in co-culture supernatants, those were har-
vested at day 6 centrifuged and filtered to remove cells and cellular debris. Cytokine
levels were analysed using the MACSplex Cytokine 12 Kit (Miltenyi Biotech) according
to manufacturer’s instructions.
IL-18 ELISA IL-18 was measured by ELISA (R&D) from centrifuged and filtered co-
culture supernatants, harvested at day 6 according to manufacturer’s instructions.
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5.2.8 Immunohistochemistry staining
Paraﬃn embedded liver sections of HCV, HBV and healthy subjects were provided
by the DZIF Biobank in cooperation with Dr. Felix Lasitschka (Project-No: i-0011).
Sections were deparaﬃnised by placing them subsequently into baths with xylol (2x),
100% ethanol (2x), 96% ethanol, 70% ethanol each for 5min and then into VE-water.
We used heat-mediated antigen retrieval. This was done by placing the slides into
boiling 1mM EDTA solution at pH8 for 20min in a steam cooker. Afterwards slides
and buﬀer was cooled for 20-30min on ice. Slides were washed twice with VE-water and
then placed for 20min at room temperature into methanol supplemented with 2% of 30%
H2O2 to block endogenous peroxidase activity. Methanol was thoroughly washed away
and liver sections on the slides circled with a grease pen. Sections were blocked with
10% Horse serum (Vectastain) + 0.1mg/ml hIgG (Sigma) in antibody diluent (DAKO)
for 20-30min at room temperature. Afterwards, the primary antibody or isotype control
was diluted (OX40L 1:25) in antibody diluent and added to the slides overnight on 4 C.
The next day slides were washed 3x 5min in PBS + 0.1% Tween20 and then incubated
with the secondary biotinylated antibody (Vectastain Elite ABC Kit) also diluted in
antibody diluent for 30min at room temperature. Antibody was washed away 3x 5min
in PBS + 0.1% Tween20. The AB-Komplex (1 part A - 1 part B solution) from the
Vectastain Elite ABC Kit which had already been incubated for 30min alone was then
added to the slides for 30min on room temperature and then washed away 3x 5min
in PBS + 0.1% Tween20 and 1x3min in PBS. The DAB-Chromogen was added to the
slides until the desired staining intensity was reached before the reaction was stopped
by putting the slides in VE-water. To counter stain the tissue, the slides were placed for
a few seconds into mayer hemalum solution and then extensively washed with tap water
and shortly in VE-water before mounting of cover slid with Fluoromount medium.
5.2.9 Statistical analysis
Statistical significance was calculated using paired two-tailed student’s t test in the
GraphPad Prism software: * p<0.05, ** p<0.01 and *** p<0.0001. All combined bar
graph data depict mean + SEM.
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The HCV replicon system has been a valuable tool to study various virological, cellular
and immunological aspects of HCV infection in vitro since its development in 1999 by
Lohmann and Bartenschlager (82 ). By far the most commonly used cell line for the
replicon system are the Huh7 and its subclone Huh7.5 hepatocellular carcinoma cell
lines. However, studies in the past have shown that upon infection, none of the tested
NK cell ligands were regulated and that NK cells could recognise and kill infected and
uninfected Huh7.5 cells to the same degree (109 ). Therefore, we established a new
system using the replicon of HCV genotype 2a: JFH1(japanese fulminant hepatitis
1) and the Huh6 hepatoblastoma cell line, which has been shown to support HCV
replication before (86 ).
6.1 The Huh6 HCV Replicon System
6.1.1 Establishment of the Huh6 Replicon System
Figure 6.1A shows the set-up of the Huh6 HCV replicon system and its subsequent
co-culture with PBMCs to study the interaction of replicon-carrying hepatocytes and
immune cells.
We used HCV replicons deleted of all structural genes, therefore unable to produce free
virions and instead equipped with a neomycin resistance gene. This subgenomic replicon
(sg-JFH1) was electroporated into the hepatoblastoma cell line Huh6 and positive clones
selected with 500µg G418 (Geneticin). Afterwards we treated some of the positive
Huh6-sgJFH1 cells with viral inhibitors BMS-553 (Daclatasvir-like inhibitor of NS5A)
and Telaprevir (inhibitor for viral protease NS3-4A) to prevent viral replication and
cure the Huh6 cell from the sg-JFH1 replicon, thereby establishing the ’Huh6 cure’ cell
line. The Huh6 cure cell line controls for possible changes due to electroporation and
G418 selection.
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HCV RNA could only be detected in the Huh6-sgJFH1 cell line, but was absent in the
parental Huh6 and the Huh6 cure line, while GAPDH levels were equal in all three lines
(Fig. 6.1B)
Fig. 6.1: The Huh6 Replicon system. Establishment of the subgenomic JFH1-neo HCV replicon
system in Huh6 cells. A) Schematic of the replicon system and PBMC co-culture. Full-length HCV
RNA from genotype 2a isolate JFH1 was deleted of core, E1/2, p7 and NS2 genes and supplemented
with a neomycin-resistance gene and an additional IRES to create the subgenomic (sg)-JFH1-neo
replicon. This replicon was electroporated into the Huh6 hepatoblastoma cell line to create the Huh6-
sgJFH1 line and replicon positive clones selected with 500µg/ml G418. Subsequent treatment of
Huh6-sgJFH1 line with the direct antivirals BMS-553 (100 nM) and Telaprevir (5µM) for 2 weeks
created the Huh6 cure line. These 3 cell lines were used in co-culture experiments with PBMCs for up
to 6 days, followed by flow cytometric analysis of PBMCs. B) qPCR analysis of Huh6, Huh6 cure and
Huh6-sgJFH1 cells using HCV RNA-specific primers and GAPDH as control. nd=not detected, n=1
6.1.2 Characterisation of the Huh6 Replicon System
After the Huh6 replicon lines were established we characterized them regarding NK
relevant surface proteins. Flow cytometry staining for 13 ligands of the most important
known inhibitory and activating NK cell receptors, such as NKG2D, DNAM, NCRs and
KIRs showed no significant alteration in any of the investigated proteins (Fig. 6.2A).
This observation was substantiated by results from RT-qPCR experiments, measuring
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mRNA levels of 7 NK cell ligands. As shown in figure 6.2B, none of the indicated
NK cell ligands showed expression values that were significantly diﬀerent between both
Huh6 - Huh6-sgJFH1 and Huh6 cure - Huh6-sgJFH1.
Fig. 6.2: Ligands for NK cells are not diﬀerentially expressed on Huh6, Huh6 cure and
Huh6-sgJFH1 cell lines. A) Flow cytometric analysis of NK cell ligands on the indicated cell lines.
Displayed are the isotype corrected geometric MFI values. Upper graph n=1, lower graph n=3-5. B)
qPCR analysis of mRNA of indicated NK cell ligands on Huh6, Huh6 cure and Huh6-sgJFH1 cells
lines. Displayed are values normalised to GAPDH expression, relative to expression in Huh6. n=2
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6.2 NK phenotype in PBMCs - Huh6-sgJFH1 co-cultures
6.2.1 Screening NK cell surface markers after co-cultures
We set up co-cultures (4-6 days) between the parental, cured or sg-JFH1 Huh6 cells
and PBMCs as described in figure 6.1A to investigate possible eﬀects of the replicon
on NK cells. Even though none of the so far tested NK cell ligands were altered
in the Huh6 cell lines by the HCV replicon, NK cells could be aﬀected via various
other mechanisms including so far unknown or untested ligands on the hepatocyte
surface, cytokines secreted by the hepatocytes or other mononuclear leukocytes within
the PBMCs after recognition of the viral RNA or cross-talk between NK cells and other
immune cells. For the co-culture we first seeded the hepatocytes and the next day
added freshly isolated PBMCs from buﬀy coats of healthy donors. After 4-6 days we
removed the PBMCs from the wells and directly analysed them by flow cytometry or
restimulated them for functional studies.
PBMCs were first gated according to forward/sideward scatter on the lymphocyte pop-
ulation, followed by exclusion of cell doublets and dead cells (i.e. 7-AAD negative or
for fixed cells AquaZombie negative cells) and finally gated on CD3 CD56+ NK cells
(Fig. 6.3A).
Figure 6.3B shows the results for one of two initial screening experiments wherein we
stained an array of 6 inhibitory, 11 activating and 2 cytokine receptors on NK cells
after the co-culture with either parental Huh6 of Huh-sgJFH1 cells. We found that
the percentage of NK cells expressing these receptors was similar in both conditions
for the majority of them. The same was true for the receptor expression per cell, the
MFI, which was also unchanged in most cases (data not shown). However, there were 2
receptors that showed an increased percentage of expression in both experiments after
co-culture with the Huh6-sgJFH1 line: the TNF receptor superfamily member OX40
and the high-aﬃnity ↵-chain of the trimeric IL-2 receptor, CD25.
6.2.2 Phenotypical and functional changes after co-culture
After the initial screening of NK cells from Huh6 co-cultures with two donors we could
confirm a highly significant upregulation of CD25 in 29 donors. A representative his-
togram and a summary of all donors, showing the increase of CD25 expression after
Huh6-sgJFH1 co-culture compared to Huh6, Huh6 cure or PBMC cultured alone is
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Fig. 6.3: CD25 and OX40 are upregulated on NK cells after co-culture with Replicon
cells Freshly isolated PBMCs from healthy donors were co-cultured with Huh6 or Huh6-sgJFH1 cells
for 4 days in medium supplemented with 100U/ml IL-2. At the end of the co-culture, PBMCs were
harvested and analysed by flow cytometry. A) Gating scheme of PBMCs after co-culture. NK cells
were distinguished by gating on single, live (7-AAD ), CD3  CD56+ lymphocytes. B) Flow cytometry
analysis of NK cells after 4 day PBMC - Huh6/ Huh6-sgJFH1 co-culture. Percentage of NK cells positive
for the indicated receptor are shown. Data is representative for 2 donors.
shown in figure 6.4A. The summary of all tested donors reveals that on average the
percentage of CD25+ NK cells is 22% +/- 2,3% or 26,5% +/- 2,5% after Huh6 or Huh6
cure culture, respectively, and that this is significantly increased to 39% +/- 3% after
Huh6-sgJFH1 co-culture.
Because expression of CD25 endows the IL-2 receptor with high aﬃnity binding to its
ligand IL-2 which is an important pro-proliferative cytokine, we further investigated the
eﬀects of virus-induced CD25 upregulation on NK cells proliferation. This was done by
labelling PBMCs before co-culture with the proliferation tracking dye carboxyfluores-
cein succinimidyl ester (CFSE). By every cell division, the amount of CFSE is divided
into half, making it possible to track the number of cell division a cell has undergone.
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Staining with CFSE before co-culture revealed that after 6 days significantly more NK
cells in the replicon-containing co-cultures (38% +/- 3%) than in the parental (21% +/-
2%) or cured (21% +/- 3%) conditions had proliferated.
Finally cytokine production and cytotoxic potential of NK cells was investigated. After
co-culture PBMCs were harvested and restimulated with either IL-12/ IL-15 for 16 h
for assessment of IFN-  production (Fig. 6.4C) or with target cells for 4 h for evaluation
of degranulation (Fig. 6.4D). The percentage of IFN-  producing NK cells from HCV-
containing cultures was roughly twice as high as from NK cells from Huh6 or Huh6
cure cultures (44% +/-6% vs. 23% +/- 3% (Huh6) or 26% +/- 3% (Huh6 cure))
(Fig. 6.4C).
However, degranulation of NK cells, as measured by the appearance of CD107a on
the plasma membrane, which is normally on the membrane of cytotoxic granules, was
similar in NK cells from all three Huh6 co-cultures against a standard target cell line
(K562), but also against Huh6 cells with or without replicon. Of note, degranulation
of NK cells, also from "PBMC only" conditions, against the Huh6 cell line war per se
at a very high level. In fact, similar degranulation against Huh6 and the classical NK
cell target K562 were observed. Furthermore NK cells from all co-cultures showed high
background degranulation of around 40% even in the absence of target cell stimulation,
whereas NK cells that were cultured within PBMCs without hepatocytes hardly showed
degranulation without target cell stimulation (Fig. 6.4D).
This "background" activation of NK cells in Huh6 and Huh6 cure co-cultures com-
pared to the "PBMC only"-condition was also visible when analysing CD25 expression,
proliferation and IFN-  production, but in these conditions the presence of the virus
furthermore enhanced NK cell activation (Fig. 6.4A-C).
These results indicate that NK cells, in the first few days after encountering HCV-
replicating hepatocytes, are activated, start to proliferate and specifically enhance their
IFN-  production, but not degranulation.
6.2.3 Characterisation of the CD25+ NK cell subset
Looking at the histograms and graphs in figure 6.4A-C it become visible that a distinct
subset of NK cells expresses high amounts of CD25, has diluted CFSE and produces
IFN- . Furthermore in all three read-outs the percentage of positive NK cells is almost
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Fig. 6.4: CD25 expression, proliferation and IFN-  production of NK cells are enhanced
in Huh6-sgJFH1 co-cultures. Freshly isolated PBMCs from healthy donors were co-cultured with
Huh6, Huh6 cure, Huh6-sgJFH1 cells or alone (PBMC only) for 6 days without the addition of cy-
tokines. At the end of the co-culture, PBMCs were harvested and analysed by flow cytometry A)-B)
or restimulated for functional analysis C)-D). A) Representative histogram and summary for CD25
expression on NK cells after co-culture. n=29 B) CFSE dilution of NK cells at the end of co-culture
for one representative donor and a summary of the percentage of cells with diluted CFSE for all donors
is shown. PBMCs were stained with the proliferation tracking fluorescent dye CFSE before co-culture.
n=18 C) IFN-  production of NK cells was measured by intracellular flow cytometry staining. PBMCs
at the end of the co-culture were restimulated for 16 h with 5µg/ml IL-12 and 50µg/ml IL-15 before
IFN-  analysis. n=10 D) PBMCs from indicated co-cultures were used in a 4 hour degranulation assay
against Huh6, Huh6 cure, Huh6-sgJFH1, K562 cells or without target cells. Percentage of NK cells
expressing CD107 after restimulation is shown for one representative out of two donors.
Gated on live, single CD3 CD56+ cells. Data depict mean + SEM, statistical significance was calcu-
lated using paired student’s t test: ** p<0.01, *** p<0.0001
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the same in all conditions. This promoted analysis of co-expression of these three mark-
ers, which is shown for one representative donor in figure 6.5A. This reveals that indeed
the same cells expressing CD25 are also the ones that have proliferated and produce
IFN- . This multi-functional subset is already apparent after co-culture with parental
and cured Huh6 cells but increases in size when the replicon is present. We further
investigated this subset in respect to its expression of NKG2A, a receptor important for
NK cell licensing. Analysis, shown for one representative donor in Fig. 6.5B, illustrates
that 13-14% of NK cells after Huh6 or Huh6 cure culture co-express CD25 and NKG2A
and only 4-5% of CD25+ cells are NKG2A . The double-positive cell population in-
creases to 33% after Huh6-sgJFH1 culture, while the CD25+ NKG2A  subset remains
almost unchanged at 5.5%.
Our results demonstrate that a CD25+ NKG2A+ multi-functional NK cell subset is
expanded after encountering HCV replicon-carrying Huh6 cells.
Fig. 6.5: The CD25+ NK cells subset proliferates, produces IFN- -producing and ex-
presses NKG2A Freshly isolated PBMCs from healthy donors were co-cultured with Huh6, Huh6
cure, Huh6-sgJFH1 cells for 6 days. At the end of the co-culture, PBMCs were harvested and analysed
by flow cytometry. A) FACS dot plot of co-expression of CFSE (upper panel) or IFN-  (lower panel)
and CD25 on NK cells after indicated co-cultures. B) FACS dot plot of co-expression of NKG2A and
CD25 on NK cells after indicated co-cultures.
One representative donor out of 5 is shown. Gated on live, single CD3 CD56+ cells.
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6.3 Role of cytokines in the HCV-dependent activation of NK
cells
6.3.1 Analysis and evaluation of cytokines in co-culture supernatants
Having observed phenotypical and functional changes of NK cells due to the presence
of sg-JFH1 replicon, we were further interested to investigate the mechanisms through
which these changes occur. Cytokines are important in shaping and regulating immune
responses and many have been implicated in HCV infection.
Therefore we determined the concentration of pro- and anti-inflammatory cytokines IL-
2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-17A, GM-CSF, TNF-↵ and IFN-↵ in the
co-culture supernatants by MACSPlex analysis and IL-18 by ELISA. IFN-↵, although
being one of the most studies cytokines in response to HCV infection and in the context
of therapy, could not be detected in our co-culture supernatants. Also undetected,
or detect at extremely low levels were IL-4, IL-5, IL-9, IL-10, IL-12p70, IL-17A, IL-
18 and TNF-↵ (Fig. 6.6C and data not shown). IL-6 and GM-CSF were present in
the co-culture supernatants and furthermore specifically increased in the Huh6-sgJFH1
condition compared to Huh6 and Huh6 cure (Fig. 6.6A-B, left column).
To investigate the importance of IL-6 and GM-CSF for the observed increase in CD25+
NK cells in our co-culture system, the cytokines were neutralised by specific antibodies
throughout the duration of the co-culture. The percentage of CD25+ NK cells after 6
days of co-culture with either Huh6, Huh6 cure or Huh6-sgJFH1 was unchanged between
isotype control and ↵IL-6 or ↵GM-CSF treated cultures (Fig. 6.6A-B, right panel). A
significant increase in CD25+ NK cells between Huh6 / Huh6 cure and Huh6-sgJFH1
cultures was observed in both isotype and neutralising conditions.
IL-18 produced by monocytes was shown to increase NK cell function after encounter
of JFH1-replicon carrying Huh7 cells in a similar co-cultures system (122 ), which
prompted us to investigate its role in our system. However, in ELISA measurements
of IL-18 in supernatants we did not detect IL-18 in Huh6 and Huh6 cure conditions
and only one of three donors from the Huh6-sgJFH1 cultures showed minimal levels of
IL-18, while it was undetectable in supernatants of the other two donors. In line with
this finding, neutralisation of IL-18 with IL-18 binding protein (IL-18BP) had no eﬀect
on the percentage of CD25+ NK cells (Fig. 6.6C).
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Many of the investigated pro- and anti-inflammatory cytokines were not or only at very
low levels in co-culture supernatants and IL-6 and GM-CSF, although specifically ele-
vated in Huh6-sgJFH1 co-cultures have no eﬀect on the percentage of CD25+ NK cells.
We could also not confirm the previously published production of IL-18 in supernatants
of Huh7-JFH1 co-cultures with PBMCs ((122 )) and neutralisation of IL-18 did not
aﬀect CD25+ NK cell percentages.
Fig. 6.6: No eﬀect of IL-6, GM-CSF and IL-18 neutralisation on NK CD25 expression
A)-C) left panel: Cytokine measurement by MACSplex A)-B) or ELISA C) of supernatants from 6
day co-culture of PBMCs with indicated Huh6 cell lines. n=3. A)-C) right panel: CD25 expression
on NK cells after diﬀerent PBMC - Huh6 co-cultures in the presence of isotype control or neutralising
antibodies/proteins. A) Cultures were supplemented with 5µg/ml neutralising ↵IL-6 or control rat
IgG1 antibody. n=8 B) Cultures were supplemented with 7.5µg/ml ↵GM-CSF of mIgG2a antibody.
n=6 C) Cultures were supplemented with 2.5µg/ml IL18BP or mIgG2a isotype control. n=7
For flow cytometric analysis cells were gated on live, single CD3 CD56+ cells. Data depict mean +
SEM, statistical significance was calculated using paired student’s t test: * p<0.05 ** p<0.01
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6.3.2 Role of IL-2 in the activation of NK cells in Replicon co-cultures
Although IL-6 and GM-CSF were specifically increased in supernatants of PBMC -
Huh6-sgJFH1 co-cultures, neutralisation of neither had an impact on NK cell activation.
Next, we investigated IL-2, as one of the few receptors that was changed on NK cells
after Huh6-sgJFH1 co-culture compared to Huh6 or Huh6 cured, was CD25, the ↵-chain
of the trimeric IL-2 receptor complex, mediating high aﬃnity binding for its ligand IL-2.
We neutralised IL-2 by addition of neutralising antibodies. While in the isotype treated
control CD25 levels on NK cells significantly increased on average from around 25% or
30% in Huh6 and Huh6 cure conditions, respectively to 40% in Huh6-sgJFH1 conditions,
CD25 upregulation was greatly reduced to around 5% after IL-2 neutralization in all
three conditions (Fig. 6.7A)
Fig. 6.7: IL-2 is important for NK cell activation in replicon co-cultures. Freshly isolated
PBMCs from healthy donors were co-cultured with Huh6, Huh6 cure, Huh6-sgJFH1 cells for 6 days.
A) Flow cytometric analysis of CD25 expression and CFSE dilution of NK cells and percentage of NK
cells among all PBMCs after indicated PBMC - Huh6 co-cultures. Cultures were supplemented with
20µg/ml neutralising ↵IL-2 or control rat IgG2a antibody. n=3 B) Flow cytometric analysis of CD25
expression and CFSE dilution of NK cells. Huh6 cell lines were either cultured with complete PBMCs
or with PBMC MACS-depleted of CD3+ cells ( CD3). n=3 C) MACSplex analysis of IL-2 from the
indicated co-culture supernatants. n=3
For flow cytometric analysis cells were gated on live, single CD3 CD56+ cells. Data depict mean +
SEM, statistical significance was calculated using paired student’s t test: * p<0.05 ** p<0.01
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The same pattern was observed for proliferation of NK cells, as measured by CFSE
dilution. Neutralisation of IL-2 completely abrogated proliferation in all conditions,
while in the isotype control again the doubling of the percentage of proliferated cells
between Huh6/Huh6 cure and Huh6-sgJFH1 conditions from around 20% to 40% is
observed.
The neutralisation of IL-2 aﬀected not only the virus-induced upregulation of CD25 and
NK cells proliferation, but also the observed "background" activation by the cancer cell
line Huh6. This global eﬀect on NK cell activation is not due to reduced survival of NK
cells, because IL-2 neutralisation had only minor eﬀect on the survival of NK cells over
the course of the 6 day co-culture. The percentage of NK cells among whole PBMCs
was similar in isotype and ↵IL-2 treated cultures and the number of 7-AAD+ NK cells
also remained unchanged (Fig. 6.7 and data not shown).
As the major source for IL-2 are typically T cells, we further investigated the role
of T cells for NK activation in our system by depleting them from PBMCs via MACS
( CD3) (Fig. 6.7B). Depletion of CD3+ cells showed a minor reduction of the percentage
of CD25+ NK cells in Huh6 and Huh6 cure cultures and a stronger eﬀect in the replicon
cultures, although results did not reach significance with the small sample size yet. The
reduction of proliferation after T cell depletion was more pronounced and could almost
be completely abrogated in all three conditions. Of note CD3+ cell depletion was only
between 80%-85% in the tested donors, providing a possible explanation why results
are not as pronounced as with IL-2 depletion (Fig. 6.7B)
IL-2 is a necessary factor for the virus-induced and virus-independent acquisition of
CD25 and proliferation of NK cells. However, it cannot be the decisive factor for
the observed phenotypic and functional changes of NK cells in HCV-replicating cul-
tures, as the levels of IL-2 in the supernatants of all culture conditions are comparable
(Fig. 6.7C). Levels of IL-2 in supernatants are also similar to Huh6 / Huh6 and Huh6-
sgJFH1 conditions when PBMCs are cultured without hepatocytes, suggesting that T
cells, or any other IL-2 producing cells, are not specifically activated by the hepatocytes
due to e.g. possible allo-recognition or even virus-recognition.
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6.4 Monocytes in the HCV-induced activation of NK cells
6.4.1 Requirement of monocytes for HCV-dependent NK cell activation
Our co-culture system is comprised of complete PBMCs, including NK cells, T cells, B
cells, monocytes and DCs and hepatocytes. We have shown that T cells are important
for the activation of NK cells in our system, most likely because of their production of
IL-2. But neutralisation of IL-2 and depletion of T cells eﬀected NK CD25 levels and
proliferation in all conditions, not only the virus-dependent NK activation. To further
dissect the possible mechanisms of virus-dependent NK cell activation we studied the
importance of other cell types within PBMCs.
Fig. 6.8: CD14+ cells are necessary for NK cell activation in co-cultures. A) Flow cytometric
analysis of CD25 expression and CFSE dilution of NK cells on day 6 after indicated co-cultures. Huh6,
Huh6 cure or Huh6-sgJFH1 cells were either cultured with complete PBMCs or with NK cells only.
NK were isolated negatively via MACS. n=2 B) Flow cytometric analysis of CD25 (n=11) and IFN- 
(n=3) expression of NK cells on day 6 after indicated co-cultures and MACSplex measurement of IFN- 
(n=3) from co-culture supernatants. The Huh6 cell lines were either cultured with complete PBMCs
or with PBMC depleted of CD14+ cell via MACS ( CD14). C) PBMCs were either cultured directly
with the indicated Huh6 cell lines or in a Transwell set-up for 6 days before flow cytometric analysis
of CD25 expression and CFSE dilution of NK cells. For the Transwell set-up the diﬀerent Huh6 lines
were cultured together with MACS-isolated CD14+ cells in the bottom and MACS-depleted of CD14
cells ( CD14) added in the upper chamber. n=2
Gated on live, single CD3 CD56+ cells. Data depict mean + SEM, statistical significance was calcu-
lated using paired student’s t test: * p<0.05, *** p<0.0001
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First of all, isolated NK cells were used in the co-culture experiments, but as expected,
also due to the absence of T cells, no increase in CD25+ NK cells and no proliferation
was observed in any of conditions (Fig. 6.8A). Even when we supplemented the co-
cultures of isolated NK cells with 20 IU/ml IL-2 to compensate for the missing T cells,
also no virus-dependent CD25 upregulation was observed (data not shown), indicating
that factors from other cells within the PBMCs, besides IL-2, are important for the
activation of NK cells.
The importance of monocytes for NK cell activation and function has been shown for
HCV and other viral infections (120 )(122 )(63 ), which prompted us to investigate their
role in our system.
CD14+ monocytes were depleted from PBMCs by MACS positive selection and the re-
maining cells ( CD14) used for co-culture experiments. Depletion of CD14+ cells specif-
ically aﬀected the percentage of CD25+ NK cells in Huh6-sgJFH1 cultures, whereas per-
centages remained almost unchanged in Huh6 and Huh6 cure conditions (Fig. 6.8B).
IFN-  production, without restimulation, was also reduced in  CD14 cultures, but also
in the control conditions. Notably, percentages of IFN-  producing NK cells were very
small and diﬀerences are only minor.
Furthermore also soluble IFN-  levels in supernatants were increased in Huh6-sgJFH1 -
PBMC cultures compared to Huh6/Huh6 cure and this upregulation was greatly reduced
in Huh6-sgJFH1 -  CD14 cultures (Fig. 6.8B).
To dig deeper into the mechanisms of monocyte - NK cell interaction we performed
transwell experiments to obtain information whether this cross-talk is mediated by
soluble or cell-bound factors. We used hepatocytes together with isolated CD14+ cells
in the lower chamber. This ensured a possible activation of the monocytes by the virus,
because for DCs it has been shown that their activation by HCV replicons is dependent
on short-range exosomal transfer of viral RNA (119 ). In the upper chamber CD14+
cell depleted PBMCs were cultured ( CD14) (Fig. 6.8C).
Analysis of CD25 expression and proliferation of NK cells revealed that in the tran-
swell setting both were almost completely abrogated. The "background" activation of
NK cells was likely gone because the contact between the hepatoblastoma cells was
missing and the virus-dependent activation was maybe gone because monocytes and
NK cells require direct cell-to-cell contact. Another possibility would be that NK cells
require stimuli by the monocytes as well as direct contact to the infected hepatocytes
(Fig. 6.8C).
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Our experiments show, that CD14+ monocytes are pivotal for the virus-dependent
activation and function of NK cells in co-culture systems of PBMCs and HCV-replicon
carrying hepatocytes and that NK cell - monocyte cross-talk is likely cell-cell-contact
dependent.
6.4.2 Phenotype of CD14+ cells in HCV co-cultures
Fig. 6.9: Phenotype of CD14+ cells in HCV+-co-cultures. PBMCs were co-cultured with
Huh6, Huh6 cure or Huh6-sgJFH1 cell lines for 48-60 hours before flow cytometric analysis. A) Flow
cytometric histograms and summaries of all donors for OX40L, CD80 and CD155 expression on CD14+
cells. n=6-9 B) Exemplary staining of indicated monocyte activation markers
Gated on monocyte gate, live, single, CD14+, Data depict mean + SEM, statistical significance was
calculated using paired student’s t test: * p<0.05, ** p<0.01
Having established the importance of monocytes for the activation of NK cells in our
system and several clues that this activation is based on direct cell-cell-contact, we
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further investigated the monocytes from our co-cultures in regard to activation markers
and potential interaction partners with NK cells.
Figure 6.9 shows that monocytes upregulated several general monocyte activation mark-
ers but also molecules which are important for a possible NK cross-talk.
One possible interaction partner with NK cells is the TNFSF member OX40L, whose
expression level was significantly higher after 60 h PBMC- Huh6-sgJFH1 culture. In
fact, in the control conditions expression of OX40L was virtually absent (Fig. 6.9A).
Further members of the TNFSF and TNFRSF, like 4-1BBL and GITR are also induced
after virus-replicating cultures (Fig. 6.9B), while other NK interaction partners, such
as DNAM-ligand CD155, were expressed on monocytes, but remained unchanged after
the diﬀerent co-cultures (Fig. 6.9A).
The T-cell co-stimulatory molecule CD80 (B7-1) is usually not expressed on naive
CD14+ cells but induced upon activation (143 ). Figure 6.9 shows in an representa-
tive histogram of one donor and a summary of all analysed donors that CD80 was
induced on monocytes in all conditions, but induction was highest in virus-containing
cultures. Other monocyte activation markers such as CD40 and CD86 were also induced
after Huh6-sgJFH1 cultures (Fig. 6.9 ).
6.5 OX40 expression on NK cells
The upregulation of OX40L on monocytes attracted our attention, because in our initial
NK receptor screen (Fig. 6.3), besides CD25, we also found OX40, the receptor for
OX40L, higher expressed on NK cells after cultures containing HCV replicons. We
could confirm this upregulation of OX40 on NK cells on a percentage and MFI level
in more donors and show that OX40 is significantly higher on NK cells after 6 days of
Huh6-sgJFH1 cultures, than after Huh6 or Huh6 cure cultures (Fig. 6.10A). On freshly
isolated NK cells, OX40 expression was virtually absent and it was only induced after
culture (data not shown).
Furthermore when we analysed OX40 expression on the CD25+ and CD25  NK cell
subsets, we found that OX40 was almost exclusively expressed on the CD25+, fur-
ther substantiating a role in the activation of this on subset that also proliferated and
produced IFN-  (Fig. 6.10 B).
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Fig. 6.10: OX40 expression on NK cells in HCV+-co-cultures. PBMCs were co-cultured with
Huh6, Huh6 cure or Huh6-sgJFH1 cell lines for 6 days and then analysed via flow cytometry. A) Rep-
resentative histogram of OX40 expression by NK cells and summaries of all donors for the percentage
of OX40+ NK cells and the geoMFI of OX40 expression on all NK cells (n=10-13). B) Exemplary
histograms of the OX40 expression on CD25+ and CD25  NK cells after co-culture.
Gated on live, single CD3 CD56+ cells. Data depict mean + SEM, statistical significance was calcu-
lated using paired student’s t test: * p<0.05, ** p<0.01
6.6 Relevance of the OX40 - OX40L interaction
6.6.1 Blocking of OX40L during co-cultures
After observing that OX40 was upregulated on NK cells and OX40L on monocytes
specifically after Huh6-sgJFH1 cultures, we sought to further investigate this inter-
action. Blocking of OX40L by monoclonal antibody Oxelumab led to a reduction of
CD25+ NK cells in Huh6-sgJFH1 conditions but also, although to a lesser yet signif-
icant extent in Huh6 and Huh6 cure conditions. Blocking of OX40L by a diﬀerent
↵OX40L antibody (clone MM0505-8S23) showed the same pattern in an initial experi-
ment with one donor. CD25 levels on NK cells from the Huh6-sgJFH1 conditions could
even be completely brought to the level observed in Huh6 conditions with this antibody
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(Fig. 6.11A). The percentage of CFSE diluted NK cells was significantly reduced upon
blocking of OX40L with Oxelumab. The significant upregulation between control and
replicon conditions seen in hIgG treated cultures was thereby greatly reduced and no
longer significant in the Oxelumab treated cultures. As for CD25 expression, Oxelumab
treatment also slightly reduced CD25 expression in control cultures. This observation
was not seen when using the MM0505-8S23 antibody. Here OX40L blocking completely
abrogated virus induced proliferation, bringing it to levels similar to uninfected con-
trols, while having almost no eﬀect on the Huh6 and Huh6 cultures. Of note, the
MM0505-8S23 antibody was only used in one initial donor (Fig. 6.11B).
Fig. 6.11: Blocking of OX40L in PBMC - Huh6-sgJFH1 co-cultures inhibits upregulation
of CD25 on NK cells and their proliferation. PBMCs were co-cultured with Huh6, Huh6 cure or
Huh6-sgJFH1 cell lines for 6 days in the presence of OX40L blocking antibodies (either Oxelumab or
MM0505-8S23) or isotype controls and then analysed by flow cytometry. A) Exemplary histograms and
summary of CD25 expression on NK cells from the indicated co-cultures. B) Exemplary histograms
and summary of CFSE dilution of NK cells from the indicated co-cultures.
Gated on live, single CD3 CD56+ cells. Oxelumab n= 3, MM0505-8S23 n=1. Data depict mean +
SEM, statistical significance was calculated using paired student’s t test: * p<0.05, ** p<0.01
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6.6.2 OX40L expression on other cells within co-cultures
The observation that blocking of OX40L also to a small extent reduced CD25 levels
and proliferation of NK cells in the uninfected co-cultures, led us to investigate the
expression of OX40L on other cells within the co-culture system. And indeed, the
Huh6, Huh6 cure and Huh6-sgJFH1 cell lines express OX40L on their surface, but all to
the same degree (Fig. 6.12A). Expression of OX40L on hepatocytes could be confirmed
by immunohistochemistry staining of primary hepatocytes in liver biopsy samples of
chronic HCV patients (Fig. 6.12B). Other cells, besides hepatocytes seem to also stain
positive for OX40L, but their exact nature has yet to be determined. No expression of
OX40L was detected within the lymphocyte gate at day 6 in any co-culture conditions
(Fig. 6.12C).
6.7 HCV-specificity of NK cell activation
Finally we wanted to address whether this activation of NK cells via OX40L on mono-
cytes that we observed in our PBMC - Huh6-sgJFH1 co-cultures was specific for HCV
and whether it was indeed due to recognition of the virus.
To address the first point we made use of two other viral replicon systems. One is
another HCV replicon system which uses Huh7 cells that carry the 9-13 replicon, which
is of a diﬀerent HCV genotype than JFH1. The 9-13 replicon is genotype 1b and
JFH1 is genotype 2a. The other one is a Dengue virus (DENV) replicon that was
also electroporated into Huh6 cells. DENV is located in the same family as HCV, the
flaviviridae family, but under a diﬀerent genus. HCV is from the hepacivirus genus,
while DENV, like many other vector-transmitted viruses (Zika virus, Yellow fever virus
or West Nile virus) is within the flavivirus genus.
We again co-cultured Huh6, Huh6 cure, Huh6-sgJFH1 as well as the Huh6-DENV, Huh7
and Huh7 9-13 cell lines together with PBMCs for 6 days and then analysed CD25
expression, proliferation and IFN-  production after IL-12/15 restimulation (Fig. 6.13).
The Huh6-DENV cultures were not significantly diﬀerent to the Huh6 cultures in any
of the read-outs, suggesting that the presence of the HCV-related DENV replicon did
not activate proliferation and IFN-  production of NK cells in this setting.
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Fig. 6.12: OX40L is expressed on hepatocytes, but not on lymphocytes after co-cultures.
A) Histogram of flow cytometry staining of OX40L on Huh6, Huh6 cure and Huh6-sgJFH1 cells. B)
Immunohistochemistry staining with ↵-OX40L or isotype antibody on liver biopsy from a chronic HCV
patient. C) Histogram of flow cytometry staining of OX40L lymphocytes after indicated co-cultures.
PBMCs were co-cultured for 6 days with indicated cell lines before flow cytometry analysis. Cell were
gated on live, single, lymphocytes.
In the co-cultures with Huh7 9-13 replicon cells, NK cells showed significantly higher
CD25 expression, although this was generally at a much lower level in all Huh7 than
in the Huh6 cultures. There was also a trend towards higher proliferation in the Huh7
9-13, than in the Huh7 cultures and finally IFN-  production was strongly increased in
the Huh7 9-13 compared to the parental cultures. This induction of IFN-  was slightly
more pronounced than in the Huh6 system (Fig. 6.13).
To address the second point, we wanted to block recognition of the viral RNA to check if
the observed activation is in fact due to virus recognition. Monocytes mainly recognise
viral RNA via their endosomal TLRs. These can be inhibited using Bafilomycin A
which blocks acidification of endosomes. Unfortunately PBMCs did not survive 6 day
treatment with Bafilomycin A at concentrations necessary to inhibit TLRs (data not
shown). Because it was shown that viral replicon RNA can be transported out of the cell
and activate DCs via exosomes, we used GW4869, an exosome inhibitor in co-culture
experiments, followed by assessment of CD25 and CFSE dilution of NK cells (Fig. 6.14).
There is a small trend, that the blocking of exosomes impairs CD25 upregulation and
proliferation in the Huh6-sgJFH1 co-cultures, but not in the control conditions. The
diﬀerences are not significant, but sample size is also still very small.
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Fig. 6.13: Diﬀerent HCV replicon systems, but not DENV replicons can activate NK
cells. PBMCs were co-cultured with Huh6, Huh6 cure, Huh6-sgJFH1, Huh6-DENV, Huh7 or Huh7
9-13 cell lines for 6 days and then analysed by flow cytometry. Cells were labelled with CFSE on day
0. For IFN-  read-out, PBMCs were restimulated for 16 h with 5µg/ml IL-12 and 50µg/ml IL-15 at
the end of the co-culture. n=3 Gated on live, single CD3 CD56+ lymphocytes. Data depict mean +
SEM, statistical significance was calculated using paired student’s t test: * p<0.05, ** p<0.01
Fig. 6.14: Assessing importance of exosome release on NK cell activation. PBMCs were co-
cultured with Huh6, Huh6 cure, Huh6-sgJFH1 cell lines for 6 days in the presence of 10µM GW4869
or equivalent amounts of DMSO. Cells were labelled with CFSE on day 0. n=3
Gated on live, single CD3 CD56+ lymphocytes. Data depict mean + SEM.
Our data show that the observed NK cell activation is seen in diﬀerent cell culture
models of HCV, but not with the related DENV and that blocking of exosome-mediated
viral recognition might reduce NK cell activation.
Taken all our results together we could show that in HCV-replicon co-cultures with
PBMCs an NK cell subset shows higher CD25 and OX40 expression and more prolif-
eration and IFN-  production. Monocytes, activated by the recognition of viral RNA,
likely contained in exosomes, are crucial for the activation and IFN-  production of NK
cells. OX40L is upregulated on monocytes, which could stimulate NK cells via OX40.
The OX40-OX40L interaction, as well as IL-2 sensing via CD25/CD122/CD132 leads
to enhanced proliferation of NK cells.
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HCV infection and the consequent HCV-related liver diseases are among the biggest
global health problems. Although virus prevalence has peaked in 1994 and is thought
to further decline, the number of HCV-related liver diseases such as fibrosis, cirrhosis
and ultimately cancer are still predicted to rise over the next decades, because those
complications only manifest after several decades of infection (144 ). DAAs treatment
can help reduce liver complications, but they are only available to a very small number
of patients and the emergence of resistant virus strains is always a risk. So in spite of the
highly eﬀective drugs against HCV, further research is needed to help create eﬀective
vaccines and other treatment options. One possible way to achieve this is to better
understand the natural immune response that leads to spontaneous viral clearance.
Previous studies have implicated a role for NK cells in the anti-HCV immune response,
but mechanistic insights are sparse. Therefore the aim of this study was to decipher
the role of NK cells in the immune response against HCV infected hepatocytes.
We show that NK cells in a co-culture of PBMCs and HCV-replicon carrying Huh6 liver
cells increase the percentage of the high-aﬃnity IL-2 receptor CD25 and the TNFSF-
receptor OX40. Functionally they have a higher proliferation and IFN-  production
than NK cells from co-cultures without replicon. NK cell activation was dependent on
IL-2, on OX40-OX40L interaction and on CD14+ monocytes.
7.1 The Replicon Systems
To gain mechanistic insights into the interplay of NK cells, infected hepatocytes and
other immune cells, we decided to use the in vitro HCV replicon system for our studies.
We tested three cell lines stably replicating the subgenomic JFH1 replicon: Huh7,
Huh6 and HepaRG. Huh7-sgJFH1 had the highest viral RNA levels. HCV RNA levels
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in Huh6-sgJFH1cell were around 20% lower than in Huh7-sgJFH1 cells and in HepaRG-
sgJFH1 cells even more than 90% lower (data not shown).
Analysing expression of NK cell ligands on parental, cured and replicon-carrying Huh7,
Huh6 and HepaRG cells, we did not observe any significant changes in any of the
cell lines (Fig. 6.2 and data not shown). This is in accordance with Stegmann et al.
who also did not observe changes in NK cell ligands after JFH1 infection of Huh7.5
cells (109 ). A possible explanation could be that due to the malignant transformation
of the Huh7 and Huh6 cells, the mainly stress-induced NK cell ligands are already
maximally induced. Indeed, we do observe expression of many NK cell ligands which
are usually absent on healthy cells already on the parental cell lines (Fig. 6.2 and
data not shown). For example NKG2D-ligands MIC-A and MIC-B were shown to be
expressed in HCV-infected liver tissue, but not in healthy livers (112 ). In our cell
lines however MIC proteins are already expressed in the parental lines (Fig. 6.2 and
data not shown). For the HepaRG line, which is a hepatic precursor cell line that
is very similar to normal non-transformed hepatocytes, viral replication might have
been too low and they also, to some extent, already express activating NK cell ligands.
Another possible explanation could be virus escape mechanisms that interfere with
upregulation of NK cells ligands, which have already been described for NKG2D-ligands
(111 ). Furthermore, many NK cell ligands still remain elusive. However, no alterations
in NK cell phenotype or function were observed after co-culture of isolated NK cells
with Huh6-sgJFH1 cells (Fig. 6.8) arguing against regulation of yet unknown NK cell
ligands.
7.2 NK cell activation in replicon co-cultures
7.2.1 Phenotype of NK cells
Even though the replicon did not directly regulate NK cell ligands on the hepatocyte
surface, NK cell phenotype was changed after several days of co-culture of PBMCs with
replicon-carrying Huh6 cells.
A higher percentage of NK cells from the Huh6-sgJFH1, than from Huh6 or Huh6 cure,
conditions expressed the high-aﬃnity chain of the IL-2 receptor, CD25 and the TNFSF-
receptor OX40 (Fig. 6.4 and 6.10). The induction of both CD25 and OX40 is also
observed on antigen-specific T cells after restimulation with cognate antigen (32 ). But
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the mechanism of this upregulation in our system, as well as on T cells, is still unclear.
Because CD25 is expressed only at low levels in CD56bright NK cells and completely
absent on CD56dim NK cells and OX40 is not expressed at all on freshly isolated NK
cells, their expression must be actively induced, as opposed to e.g. outgrowth of a
subset already expressing the receptors (47 ). Of note, the subset expressing high levels
of CD25 and OX40 also proliferates more (Fig. 6.4), which can then further support
the increase in percentage.
We have observed that expression levels of OX40 on NK cells correlate with levels of
IL-2 present in the co-cultures. When co-cultures were supplemented with 100U/ml
IL-2, the overall levels of OX40 were higher than in co-cultures without exogenous
IL-2 (compare OX40 levels in figure 6.3 (100U/ml IL-2) and 6.10 (no added IL-2)).
Also when the same donors were cultured with or without IL-2, OX40 was present on
approximately 50% of NK cells in cultures with 100U/ml IL-2 and only on around
5-10% on NK cells cultured without added IL-2 (data not shown). For T cells it has
already been shown that IL-2 can induce and enhance the expression of OX40 and other
TNFRSF members, although the primary OX40-inducing stimulus in T cell is TCR and
CD28 or CD40 engagement (30 ) (31 ) (145 ). The induction of OX40 on NK cells in our
co-culture system could hence be facilitated by IL-2. Although IL-2 levels are similar
in all tested conditions (Fig. 6.7), OX40 induction could be higher in Huh6-sgJFH1
conditions because signalling of IL-2 is enhanced due to expression of CD25. It has
been shown that cells with and without CD25 expression can proliferate equally under
high IL-2 concentrations (> 100 U/ml), but only CD25 expressing cells can proliferate
under low IL-2 concentrations, such as in our system (only around 20 pg/ml) (146 )
(147 ). Thus, enhanced IL-2 signalling due to expression of CD25 in Huh6-sgJFH1
conditions could contribute to the enhanced OX40 expression on NK cells. However,
blocking of OX40L-OX40 interaction also prevented CD25 upregulation, which would
argue against a sequential regulation of CD25 and OX40. Furthermore in time-course
experiments, OX40 and CD25 expression were increasing rather simultaneously (data
not shown), arguing for a more complex transcriptional regulation.
CD25 upregulation on NK cells is observed in a number of situations, such as viral
or bacterial infections, vaccination or cytokine treatment (63 )(147 )(148 ) (49 )(50 ). In
many of the above mentioned scenarios, the pro-inflammatory cytokines IL-12 and IL-
18, which are often produced during viral or bacterial infections, are involved in the
induction of CD25. Lee et al. even observed upregulation of CD25 only on a subset of
NK cells after IL-12 stimulation, similar to our observations. However, neither IL-12p70
85
7 Discussion
nor IL-18 could be detected by MACSplex or ELISA, respectively, in our co-culture
supernatants (Fig. 6.6C and data not shown) and neutralisation of IL-12 or IL-18 by
neutralising agents did not aﬀect CD25 levels on NK cells (Fig. 6.6C and data not
shown). Recently also IL-27, a member of the IL-12 cytokine family was shown to be
able to induce CD25 (149 ) and to be expressed by macrophages after TLR stimulation
(150 ). IL-27 could therefore be a candidate for the virus-dependent induction of CD25
in our system. Macrophages/Monocytes are a likely source of the HCV-dependent
stimulus for upregulation of CD25 and OX40, as without them CD25 levels in control
and sg-JFH1 conditions are similar (Fig. 6.8).
We also observe that neutralisation of IL-2 abrogates CD25 expression almost com-
pletely, showing that IL-2 itself is necessary for the expression of its receptor. But
CD25 expression was abrogated in all conditions, with and without replicon, and IL-2 is
present at equal levels in all conditions, indicating that IL-2 is not the virus-dependent
stimulus that enhances CD25 expression specifically in the Huh6-sgJFH1 conditions
(Fig. 6.7).
Further investigations are needed to determine the factors induced by the HCV replicon
which trigger the upregulation of CD25 and OX40 on NK cells.
7.2.2 Donor-to-donor variability
Working with primary human material often results in high experimental donor-to-
donor variability. We also observed that some donors had a strong induction of e.g.
CD25 or IFN-  in response to the replicon, while others showed little or no signs of
activation. However, the majority of the donors’ NK cells were activated by the replicon.
In more than 50% of cases an increase in the percentage of CD25 of more than 1.5-
fold between Huh6-sgJFH1 and Huh6 conditions was observed. The donor with the
strongest activation had more then 6 times more CD25+ NK cells in the Huh6-sgJFH1
than in the Huh6 culture.
Possible reasons for these diﬀerences are most likely manifold and include sex, age,
genetic factors (such as SNPs), or a diﬀerent KIR - MHC repertoire, just to name
a few. Further influencing factors could be previous infections or co-infections (eg.
HCMV, HSV, EBV) with other viruses or pathogens. The phenomenon that other
infections influence the immune response to a new pathogen has been shown for T cells.
Previously formed memory T cells can cross-react with similar peptides from a diﬀerent
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pathogen and therefore excert strong and fast immune responses even after a primary
pathogen encounter (151 ). There could be a similar mechanism in NK cells. Infection
with HCMV or treatment with a combination of IL-12/15/18, cytokines often induced
during viral infection, induce so-called adaptive or memory-like NK cells. These NK
cells have been shown to have long-lasting heightened eﬀector potential (ADCC and
IFN-  production) to pathogen-unspecific stimuli (152 )(153 ) (154 ).
We have observed that NK cells that show a strong virus-dependent activation are in
most cases already more activated by encountering the parental Huh6 cancer cell line
than NK cells from donors that are not or only slightly activated by the replicon (data
not shown). This argues that NK cells from these donors are in general more easily
activated and show stronger eﬀector responses, which could be because of previous
stimuli such as HCMV.
Because monocytes are essential for the activation of NK cells in our system, diﬀerences
in their activation potential and virus recognition could also aﬀect NK cells. It was,
for example, previously shown that a SNP in TLR-7 aﬀects the progression of HCV
infection (155 ).
7.2.3 Function of NK cells
NK cells from PBMC - Huh6-sgJFH1 co-cultures showed higher IFN-  production
with and without IL-12/15 restimulation and stronger proliferation than NK cells from
PBMC - Huh6 / Huh6 cure co-cultures. Degranulation, as measured by the appearance
of CD107a on the NK cell plasma membrane, against standard NK cell target lines
(K562) and the Huh6 cells with and without replicon was, however, similar in NK cells
from all diﬀerent co-culture conditions (Fig. 6.4).
Previous studies using similar PBMC co-culture systems, albeit with JFH1 infected
Huh7.5 or Huh7-sgJFH1 cells and for only 24 hours, did also observe an increase in NK
cell IFN-  production (120 )(122 ). Yet, Serti et al. additionally reported an increase in
NK cell cytotoxicity, which is also often reported for NK cells isolated from the blood of
chronic HCV patients (156 )(137 ). Mechanistically the increase in NK cell cytotoxicity
was attributed to altered IFN-↵ signalling in chronic HCV patients, showing preferen-
tial STAT1 over STAT4 phosphorylation, which polarises NK cell towards cytotoxicity
instead of IFN-  production (137 ). Of note, in the chronic phase this altered signalling
rather contributes to liver injury than viral clearance and also in the replicon in vitro
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system viral replication was mostly influenced by IFN-  production and not by cytotox-
icity. Possible reasons for the discrepancy to our observations are the source of PBMCs
and the duration of our co-cultures. PBMCs isolated from buﬀy coats, rather than
from fresh blood contain very low numbers, if any pDCs, the main producers of IFN-↵.
Additionally pDCs have a very short live span in vitro, which is maybe why we do not
detect IFN-↵ in co-culture supernatants from day 6 and subsequently no increase in
NK cell cytotoxicity.
Proliferation of NK cells could be almost entirely abolished in all conditions by neutral-
isation of IL-2 (Fig. 6.7), indicating that IL-2, independent of the virus, is essential for
the proliferation of all NK cells. However, under limiting IL-2 concentration the higher
CD25 expression in the replicon-containing conditions probably leads to a stronger pro-
liferation in the Huh6-sgJFH1 conditions.
Blocking of OX40L-binding to OX40 also aﬀected proliferation, although only slightly
in the Huh6 and Huh6 cure conditions and to a greater extent in the Huh6-sgJFH1 co-
cultures (Fig. 6.11), which suggests that the proliferation dependent on OX40 signals
might be induced by the virus. The dependence on IL-2 and OX40 in regard to IFN- 
production of NK cells in our system has yet to be evaluated.
The influence of OX40 signalling on NK cell proliferation is in line with previous reports,
in which treatment of late-stage cancer patients with an agonistic OX40 antibody led
to higher proliferation of CD4+, CD8+ T cell and NK cells, but not Treg cells (36 ).
The finding that the CD25+OX40+ subset of cells are the main producers of IFN-  and
show the strongest proliferation is also similar to findings on CD4 T cells. Zaunders
et al. could show that a subset of human CD4 T cells expresses CD25 and OX40 af-
ter antigen-stimulation. Only the double-positive subset produced significant amounts
of IFN-  and it showed the strongest proliferation (32 ). In mouse T cells OX40 sig-
nalling was shown to be crucial for the control of persistent viral infections (lymphocytic
choriomeningitis virus (LCMV)) by promoting T cell survival through the activation of
NF-B and Akt which subsequently upregulates anti-apoptotic Bcl-2 family members
(157 ). But in mouse T cells, proliferation and function were not aﬀected by OX40
signalling. The importance of OX40 and the interplay with IL-2R, TCR and CD28
signalling for survival, proliferation and IFN-  production were also shown in mouse
NKT cells, where signalling through OX40 is thought to increase important transcrip-
tion factors such as nuclear factor of activated T-cells (NFAT), NF-B and Tbet which
enhance IL-2 and IFN-  production (158 ).
There are several indications from human T cells and mouse T and NKT cells that
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OX40 signalling is mediating survival, proliferation and IFN-  production and that the
CD25 and OX40 pathways interact with each other, supporting our findings. However,
to our knowledge, OX40 signalling has not been addressed in NK cells.
7.2.4 Characterisation of the activated NK cell subset
We consistently observe that only a specific subset of NK cells expresses CD25, prolifer-
ates and produces high amounts of IFN-  (Fig. 6.5A). This subset is almost completely
positive for NKG2A (Fig. 6.5B) and expresses OX40 (Fig. 6.10B). The exact reasons
why this specific subset is activated in our co-cultures remains elusive.
One possible explanation could be the KIR repertoire and the KIR - MHC-I matching
of NK cells and Huh6 cells. Because the expression of the inhibitory KIR receptors is
stochastic, every NK cell can express varying KIR numbers (0-4) and alleles leading to
a diﬀerent inhibitory potential by the interaction with the MHC-I+ Huh6 cells. HLA
typing of the Huh6 cells revealed expression of all 6 possible MHC-I molecules, including
two HLA-C alleles, both of the C1 type (data not shown). HLA-C1 and -C2 are distin-
guished by either expression of the amino acid asparagine or lysin on position 80 and
they can bind to diﬀerent KIRs (159 ). To address this question experimentally, further
stainings of diﬀerent KIRs and KIR typing of each donor needs to be performed.
Beside the direct inhibitory potential of the KIRs, the NK cell education and licensing,
which is largely dependent on KIR and NKG2A could also play a role in their subsequent
activation potential. The fact that the activated subset is almost completely NKG2A+
points in this direction, but further investigation into the HLA and KIR haplotypes of
the donors would be necessary to answer this question.
The finding that the responding subset expresses NKG2A could also indicate that the
CD56bright NK cells is the subset specifically responding in our co-cultures, because
the CD56bright NK cells are known to all express NKG2A, while only about half of the
CD56dim NK cells express this receptor (17 ). However, the separation of those two
subsets in flow cytometric analyses after the co-cultures is in most cases impossible
(data not shown). The observation that they produce higher amounts of cytokines,
but cytotoxicity is not aﬀected in our studies would also fit to the classical definition of
those two subsets, in which the CD56bright NK cells are the main producers of cytokines,
while the CD56dim subset primarily kills target cells.
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Another possible explanation could be the distribution of other receptors that are re-
sponsible for the induction of CD25 or OX40 on this subset. The receptor for the before
mentioned IL-27 that could be a potential candidate for the virus-dependent NK cell
activation, because it is secreted by monocytes after TLR stimulation and can induce
CD25 expression, is expressed at a higher level in the CD56bright NK cell subset (160 ).
However, the activation of this specific NK cell subset is also, although to a lesser extent,
seen in the control conditions without virus, arguing for a virus-independent mechanism,
such as the KIR distribution or licensing status of NK cells or a coexistence of both
virus-dependent and independent mechanisms.
A similar subset of cells expressing high levels of CD25 and OX40 and increased IFN- 
production was observed in CD4+ T cells. Analysis of this subset revealed that those are
antigen-specific memory CD4+ cells. In fact, a clinical assay has been developed that
uses the induction of CD25 and OX40 after antigen-stimulation to determine whether
a patient has memory CD4 T cells for a specific pathogen (32 ). The "OX40 assay" was
subsequently shown to be also valid HCV antigens (33 ). Furthermore OX40 is not only
a marker of memory CD4+ T cells, but is actively involved in the generation of CD4+,
as well as CD8+ memory T cells, e.g. by diminishing activation-induced cell death in
T cells after antigen priming (161 ).
Recently, adaptive or memory-like NK cells were described in mice and humans. Inter-
estingly, CD25 was one of the markers that was increased on IL-12/15/18 stimulated
NK cells and after HCMV infection. Both scenarios which generate those adaptive NK
cells(153 ) (63 ). Furthermore, in mice, memory NK cells were specifically found to re-
side in the liver (162 ), however in humans initial studies are still controversial regarding
memory phenotype of NK cells in the liver (163 )(164 ).
In the context of these findings on memory T and adaptive NK cells it is tempting to
speculate that the expanding subset in our co-cultures would be endowed with long-
lasting enhanced eﬀector functions.
Those adaptive NK cells have already been detected in chronic HCV patients, although
only in the context of HCMV co-infection. An increase in the NKG2C+ NK cell subset,
which was described to posses those adaptive features, was seen in chronic HCV and
HBV patients that were HCMV+ and this subset was highly functional (165 ). More
recently negativity for the adaptor protein Fc"RI  is used as a marker for adaptive
NK cells. This Fc"RI   subset largely, but not completely overlaps with NKG2C
expression and is expanded in HCMV+ healthy subjects as well as in HCMV+ chronic
HCV patients. Furthermore HCV+HCMV+ patients who posses the Fc"RI  negative
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NK subset show reduced liver enzymes and fibrosis stage (166 ).
Further evaluation of cell with potential long term eﬀector functions, by e.g. evaluating
Fc"RI  expression of the expanded subset in our cultures would therefore be a worthy
endeavour.
7.3 Importance of CD14+ cells for the activation of NK cells
The depletion of CD14+ cells from PBMCs in our co-cultures prevented the induction
of CD25 and IFN-  on NK cells in Huh6-sgJFH1 conditions.
The ability of PAMP-stimulated monocytes or macrophages to activate NK cells and
the importance of monocyte/macrophage - NK cell cross-talk has been shown for many
types of viral, bacterial and parasitic infections, whereby the NK stimulation can be
achieved either via cytokines or via cell-cell-contact (60 ).
IL-12 secreted by inflammatory monocytes in HCMV infection is for example important
for the expansion of adaptive NK cells and the increase of CD25 on those NK cells
(63 ).
In the liver, IL-12 and IL-18 produced by Kupﬀer cells after polyI:C treatment were
shown to stimulate liver-resident NK cells to produce IFN-  (167 ). For HCV infection
NK activation dependent on accessory cells (monocytes and dendritic cells) was shown
in several in vitro studies, including the results presented in this thesis. Serti et al.,
Zhang et al. and we unanimously report that monocytes are important for NK cell
activation in PBMC co-cultures with JFH1 infected or replicon-carrying hepatocytes
and that isolated NK cells in co-cultures are not activated (120 ) (122 ) (Fig. 6.8). In
the report by Serti et al. it was shown that IL-18 produced by monocytes in JFH1
infected Huh7.5 cell co-cultures can activate NK cells to produce higher amounts of
IFN-  (122 ). However, this finding was not confirmed by Zhang et al. using the same
infection system, neither could we see production or an importance of IL-18 for NK
cells in the Huh6 subgenomic replicon system (120 ) (Fig. 6.6). Zhang et al. traced the
NK cell activation back to IFN-↵ produced by pDCs, although they also saw a role for
monocytes, as NK cells + pDCs in co-culture with Huh7.5-JFH1 cells did not activate
NK cells, but using NK cells + pDCs + monocytes resulted in NK cell activation.
Similar to our observations, NK cells + monocytes alone also did not result in NK cell
activation (120 ) (data not shown).
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Besides IL-12, IL-18 and IFN-↵, other cytokines such as IL-15, IL-10 or IL-23 were
already reported in human and mouse studies to facilitate monocyte/macrophage cross-
talk (60 ).
Besides cytokine stimulation, cell-cell-contact between monocytes/macrophages and NK
cells is often necessary for NK cell activation.
Many studies have demonstrated the expression of NK cell ligands on monocytes and
macrophages after stimulation and their interaction with activating receptors, such as
NKG2D, 2B4, NKp30, NKp46, NKp80 or DNAM-1 on NK cells, leading to IFN- 
production or cytotoxicity (60 )(61 ). Haller et al. could also show that Lactobacillus-
treated macrophages co-cultured with NK cells led to upregulation of CD25 on NK cells
and was dependent on cell-cell-contact. The nature of the interaction was, however, not
further defined (148 ).
We identified OX40L as one potential NK-cell activating ligand that is upregulated
on monocytes in replicon-containing co-cultures. Monocytes were previously shown to
express OX40L after diﬀerent inflammatory stimuli, including HCV. Piconese et al.
could stain OX40L on monocytes, especially on M2-like monocytes, from liver samples
of chronic HCV patients (168 ). Furthermore Zhang et al. could show that OX40L
expression on peripheral monocytes was induced in chronic HCV patients and that
OX40L expression correlated with rapid and early virological response after peg-IFN-
↵/Ribavirin treatment. As a mechanisms of OX40L upregulation they identified TLR-2-
mediated recognition of the viral Core protein (169 ). This cannot be the mechanisms of
OX40L induction in our study, because the subgenomic replicon does not contain Core
protein. Also, when we, in collaboration with Robert Thimme and Maike Hofmann
from the University Hospital Freiburg, addressed OX40L expression on monocytes in
a cohort of chronic HCV patients, we could not stain OX40L on peripheral monocytes
(data not shown). Both of the above mentioned studies did not address interaction of
OX40L-expressing monocytes with NK cells. Piconese et al. focussed on the interaction
with Treg cells, which highly express OX40 in non-cirrhotic and tumour liver tissues
of HCV patients. Triggering of OX40 on Tregs supports the suppressive phenotype of
Treg cells and thereby favours tumour progression. On the other hand, blocking of
OX40L on monocytes suppressed the functions of CD4+ T cells and OX40L expression
on monocytes in HCV patients was associated with a higher antigen-specific CD4+ T
cell response (169 ).
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So far, the impact of OX40L expression on monocytes for NK cells was, to our knowl-
edge, never studied. Two studies in mice reported the interaction of OX40L-expressing
pDCs and mast cells, respectively, with NK cells and one human study in 2012 by Mar-
tinet et al. showed the impact of OX40L on pDCs for NK cell activation in chronic
HBV patients (34 ) (35 ) (37 ). Liu et al. show in a B16 tumour model with injec-
tion of CpG-activated pDCs that the recruitment to the tumour and activation of T
cells is dependent on NK cells. The NK cells themselves are recruited by the activated
pDCs via CCR5 and are activated via IFN-↵ and OX40L, wherein IFN-↵ primarily
stimulates cytotoxicity and OX40L NK IFN-  production. They could show the up-
regulation of OX40L on CpG activated pDCs and also show OX40 expression on NK
cells. This is, to our knowledge, the only report showing OX40 expression on NK cells
(34 ). Vosskuhl et al. also show that IFN-  production, but not cytotoxicity, of NK
cells is partly induced by OX40L expression on LPS-activated Mast cells in mice. They,
however, failed to detect corresponding OX40 expression on NK cells (35 ). Both studies
indicate that OX40L-OX40 interaction increases IFN-  production, but not NK cyto-
toxicity. Although we so far just directly addressed the impact of OX40L on CD25
expression and proliferation (Fig. 6.11) and only showed impaired IFN-  production
after CD14 depletion (Fig. 6.8), the above mentioned findings favour the speculation
that OX40L blocking would also decrease IFN-  production in our system. Moreover,
in the human system an eﬀect of stimulated pDCs on IFN-  production was also ob-
served. CpG-stimulated pDCs from chronic aviremic HBV patients in co-culture with
heterologous NK cells produced higher amounts of IFN-  than NK from co-cultures
with unstimulated pDCs. This was not observed with pDCs from viremic patients due
to an impairment of pDC activation by the virus. The same was true for NK cell
degranulation. Stimulation of NK cells with soluble OX40L and IFN-↵ enhanced NK
degranulation. Of note, IFN-  production was not addressed, neither was the eﬀect
of soluble OX40L alone. Therefore, one could speculate that the eﬀects on NK cell
degranulation are primarily mediated via IFN-↵ in this setting, which would be in line
with previous reports. They could furthermore show that OX40L expression on pDCs
negatively correlated with viral load and Hepatitis B surface antigen and that the virus
interfered with pDC expression of OX40L, but not with other TNFSF members, such
as 4-1BBL, ICOSL or GITRL. Although they claim that OX40L interacts with OX40
on NK cells, they do not show OX40 expression on NK cells (37 ).
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7.3.1 OX40L expression
Even though we observed upregulation of OX40 on NK cells and of OX40L on monocytes
in co-cultures with Huh6-sgJFH1 cells and reduced NK proliferation and CD25 upregu-
lation after blocking of OX40L, we also detected OX40L on Huh6 cells and hepatocytes
in patient liver samples (Fig. 6.9, 6.10, 6.11 and 6.12). Because OX40 is expressed at
higher levels and on more NK cells only on the replicon-containing conditions, blocking
of the OX40L/OX40 axis could primarily aﬀect NK cell activation here, irrespective
of the expression of OX40L on monocytes. To distinguish the impact of OX40L on
monocytes and hepatocytes, we tried to knock-down OX40L expression in Huh6 cells
by shRNA, but so far, this approach was not successful (data not shown). Because
Huh7 cells do not express OX40L (data not shown), but show similar NK activation
after replicon co-culture (Huh7 9-13), further analysis using OX40L blocking in this
setting could also provide answers to this question. Of note, the Huh6 system could be
better suited to serve as a model for this pathway in vitro because primary hepatocytes
in HCV livers, like the Huh6 cells express OX40L, while Huh7 cells do not.
Although we so far cannot tell whether OX40 is activated by OX40L on monocytes or
OX40L on the Huh6 cells and we do not know whether in the Huh7 9-13 system NK
activation will be dependent on similar pathways, we know that monocytes are impor-
tant for the virus-dependent activation and that depletion of monocytes and blocking
of OX40L had very similar eﬀects on NK CD25 expression. This favours a scenario in
which the recognition of OX40L on monocytes is important, but CD14 cells could also
provide additional stimuli for NK cells, e.g. to promote upregulation of OX40 or CD25.
A possible candidate could be the before mentioned IL-27 (chapter 7.2.1). Although
the Transwell experiments pointed to a cell-cell-contact dependent stimulus, cytokines
could additionally play a role.
7.4 NK cell activation by diﬀerent viruses and viral strains
So far, all our findings are based on the Huh6 replicon system using the JFH1 HCV
strain, which is genotype 2a. Therefore we further wanted to investigate other cell
lines, HCV genotypes and related viruses for their potential to activate NK cells in
our co-culture settings. As already discussed in chapter 7.1, we could not see NK cell
activation in co-cultures with Huh7-sgJFH1 or HepaRG-sgJFH1 cells (data not shown).
However, when the HCV subgenomic replicon 9-13 (genotype 1b) in Huh7 cells was used
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in PBMC co-cultures, we did observe NK cell activation (Fig. 6.13), showing that also
other HCV genotypes are capable of inducing a similar NK cell activation (significantly
higher CD25 levels and IFN-  production and increased proliferation). Furthermore,
it shows that also Huh7 cells can activate NK cells in this setting, depending on the
replicon they carry. The viral RNA levels between Huh7-sgJFH1 and Huh7 9-13 cells
are comparable. In some experiments 9-13 RNA was slightly higher, in others slightly
lower than the JFH1 RNA, which most likely depends on the cell cycle and cell passage
(data not shown), excluding the RNA levels as a possible reason for the diﬀerent eﬀects
on NK cell activation. Because NK cells are activated via CD14+ monocytes and they
are most likely stimulated via the recognition of viral RNA in exosomes, it is tempting
to speculate that the RNA levels present in exosomes is diﬀerent in the two strains.
However, further experiments are needed to determine whether the mechanisms of NK
cell activation are the same in the Huh6-sgJFH1 and the Huh7 9-13 system. Establish-
ment of Huh6 9-13 cell lines would also help to diﬀerentiate between the influences of
the cell lines and the replicons.
When comparing the data from the Huh6 and the Huh7 replicon systems another obser-
vation can be made. The "background activation" that is independent of the virus, is
much higher in co-cultures with the parental Huh6 or Huh6 cure cell line, than with the
Huh7 cell line. The Huh6 cell themselves seem to have a higher potential to activate
NK cell than the Huh7 cells. Huh6 and Huh7 cells both express many, but not the
same, NK cell ligands, which could be the reason for these diﬀerences. One ligand that
is diﬀerentially expressed by the two cell lines that could be of particular interest is,
as already mentioned, OX40L, which is expressed by the Huh6, but not by the Huh7
cells.
To evaluate if the activation of NK cells is specific to HCV or if other viruses can do the
same, we co-cultured PBMCs with Huh6 cells containing a subgenomic Dengue virus
replicon, another member of the flaviviridae family. NK cells from the Huh6-DENV
co-cultures did not show significant diﬀerences in the percentage of CD25, proliferation
or IFN-  production when compared to parental Huh6 cells (Fig. 6.13). One reason
why Dengue virus did not activate NK cells in our setting, could be that DENV is
not known to pack its RNA into exosomes (170 ). This could prevent recognition by
monocytes and subsequent NK cell activation. So far the only flaviviridae member that
has been shown to do so is HCV. Interestingly, Hepatitis A virus has been shown to
be transmitted via viral RNA in exosomes as well and could therefore be an interesting
candidate to study (170 ). Furthermore it would be interesting to study DENV in a
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system containing free virions, which can be recognised by monocytes to see whether
NK cells can be activated in this setting and whether it uses the same pathway.
7.5 Final conclusions
We have described a novel pathway of NK cell activation in Hepatitis C Virus infec-
tion, which is dependent on OX40L, CD14+ monocytes and IL-2 to stimulate NK cell
proliferation and IFN-  production.
We could show upregulation of CD25 and OX40 on NK cells after PBMC - Huh6-
sgJFH1 co-culture and enhanced proliferation and IFN-  production of NK cells. This
is in line with other reports from T cells and NK cells in mice and humans in which
CD25 and OX40 stimulation led to enhanced proliferation, IFN-  production, but not
cytotoxicity. To our knowledge, this is the first report showing the expression of OX40
on human NK cells.
There is accumulating evidence that the interaction of accessory cells and NK cells in
HCV is the main route for NK cell activation. Monocytes have been shown to stimulate
NK cells in HCV infection via soluble (e.g. IL-18) or cell-cell-contact dependent factors
(122 ) (120 ). We identified OX40L as one potential cell-cell-contact dependent factor.
So far, the interaction of OX40L on monocytes or hepatocytes and OX40 on NK cells
has not been studied and presents interesting opportunities for future investigations.
Besides OX40L and monocytes, IL-2 was also necessary to activate NK cells in our
system and this was most likely produced by T cells. However, IL-2 levels were similar
in all conditions including PBMCs cultured alone. Therefore production of IL-2 is not
virus-dependent and also does not results from allogeneic stimulation of T cells by the
hepatocytes.
So far, our experiments were performed with peripheral NK cells and PBMCs from
healthy donors and hepatoma cell lines carrying the subgenomic HCV replicon. There
is some evidence that the pathway we identified might be of importance for patients and
outcome of infection. OX40L expression has been shown in HCV patients on peripheral
blood monocytes (169 ), which contributed to an early response to IFN-↵/Ribavirin
treatment, probably via CD4+ T cells. Vica versa, in HBV patients low levels of OX40L
on pDCs was correlated with high viral load and impaired NK cell activation (37 ).
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We could show OX40L expression on hepatocytes and other intra-hepatic cells in HCV
patient livers (Fig. 6.12). To address whether those include macrophages/ Kupﬀer cells
we want to perform co-staining of OX40L with macrophage/ Kupﬀer cell markers and
furthermore OX40 and NK cell co-stainings. However, further studies are needed to
investigate the relevance for the OX40-OX40L pathway for NK cell activation in the
liver in vivo.
Exploitation of this pathway could be a possible avenue for new HCV treatments. OX40
agonistic antibodies are at present in clinical trials for cancer patients but could also be
of use in HCV therapy. In fact, OX40 agonist therapy could have several advantages
compared to IFN-↵/Ribavirin treatment. In contrast to the type I IFN receptors which
are constitutively expressed on a wide variety of hematopoietic and non-hematopoietic
cells, OX40 is only expressed on NK cells and on antigen-specific T cells after activation.
OX40 expression patterns in the liver have yet to be evaluated, but if OX40 is expressed
in areas of viral replication, activation of immune cells could happen locally at the
infection sites. This would decrease side eﬀects, which are severe in IFN-↵/Ribavirin
therapy and often lead to premature termination of treatment. Side-eﬀects in clinical
studies using ↵-OX40 therapy in cancer patients were already reported to be acceptable
(36 ).
Furthermore, in contrast to IFN-↵, which was shown in many studies to mainly increase
NK cell cytotoxicity, triggering of OX40 stimulates IFN-  production by NK cells and
T cells, which has been shown to be more important to virus control than cytotoxicity
(122 ) and could also limit the extent of liver injury caused by cytotoxic T and NK
cells.
However, treatment with agonistic OX40 antibodies should also be considered with
caution, because in mice it was shown that in chronic infections treatment with ↵-
OX40 antibodies can leads to severe CD8+ T cell-mediated immunopathology (171 ).
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8 Acronyms
ADCC antibody-dependent cellular cytotoxicity
ALR Aim2-like receptor
ALT alanine aminotransferase
APC antigen-presenting cell
BCR B cell receptor
CFSE carboxyfluorescein succinimidyl ester
DAA direct acting antiviral
DC dendritic cell
DENV Dengue virus
GAS gamma Interferon activation site
GM-CSF granulocyte macrophage colony-stimulating factor
HA haemagglutinin
HCMV human cytomegalovirus
HCV Hepatitis C virus
HCVcc cell-culture derived HCV
HCVpp HCV pseudoparticles
HIV human immunodeficiency virus
HN Hemagglutinin neuraminidases
HSPG heparan sulfate proteoglycans
IDU intravenous drug user
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8 Acronyms
IL-10 Interleukin-10
IL-18BP IL-18 binding protein
ILC innate lymphoid cell
IFN Interferon
IFN-  Interferon-gamma
iNOS inducible nitric oxide synthase
IRES internal ribosomal entry site
ISG IFN-stimulated genes
ITAM immunoreceptor tyrosine-based activation motif
ITIM Immunoreceptor tyrosine-based inhibitory motif
JAK Janus kinase
JFH1 japanese fulminant hepatitis 1
KIR killer-cell immunoglobulin-like receptor
LCMV lymphocytic choriomeningitis virus
LDL low-density lipoproteins
LDLR low-density lipoprotein receptor
LGP2 laboratory of genetics and physiology 2
LPS lipopolysaccharide
MACS magnetic-activated cell sorting
MAIT mucosal-associated invariant T cell
MAVS mitochondrial antiviral signaling protein
MCMV murine cytomegalovirus
MDA5 melanoma diﬀerentiation gene 5
MDSC myeloid-derived suppressor cell
MHC major histocompatibility complex
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MIC-A MHC class I polypeptide-related sequence A
MIC-B MHC class I polypeptide-related sequence B
MLV murine leukemia virus
NCAM neural cell adhesion molecule
NCR natural cytotoxicity receptor
NFAT nuclear factor of activated T-cells
NF-B nuclear factor kappa-light-chain-enhancer of activated B cell
NK Natural killer
NKG2D Natural Killer group 2, member D
NLR NOD-like receptor
NO nitric oxide
ORF open reading frame
PAMP pathogen-associated molecular pattern
PBMC peripheral blood mononuclear cell
PCNA proliferating cell nuclear antigen
PHH primary human hepatocytes
PI3K phosphatidylinositol-3 kinase
PRR pattern recognition receptor
RAG recombination-activating gene
RIG-I retinoic acid-inducible gene-I
RLR Rig-like receptor
ROS reactive oxygen species
SCID severe combined immune deficiency
SNP single nucleotide polymorphism
SR-BI scavenger receptor BI
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8 Acronyms
STAT signal transducers and activators of transcription
SVR sustained virological response
TAP transporter associated with antigen-processing
TCR T cell receptor
TGF-  transforming growth factor-beta
TLR Toll-like receptor
TNF-↵ tumor necrosis factor-alpha
TNFR tumor necrosis factor receptor
TNFRSF tumor necrosis factor receptor superfamily
TNFSF tumor necrosis factor superfamily
TRAIL TNF-related apoptosis inducing ligand
TRAIL-R TRAIL-receptor
TRAF TNFR-associated factor
Treg regulatory T cell
ULBP UL16 binding protein
UTR untranslated region
VLDL very low-density lipoproteins
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